



(86) Date de dépôt PCT/PCT Filing Date: 1994/03/23
(87) Date publication PCT/PCT Publication Date: 1994/10/13
(45) Date de délivrance/Issue Date: 2006/07/25
(85) Entrée phase nationale/National Entry: 1995/09/29
(86) N° demande PCT/PCT Application No.: US 1994/003004
(87) N° publication PCT/PCT Publication No.: 1994/022852
(30) Priorité/Priority: 1993/03/31 (US08/040,731)


(51) Cl.Int./Int.Cl. *C07D 215/12* (2006.01),
A61K 31/495 (2006.01), *A61K 31/47* (2006.01),
A61K 31/535 (2006.01), *C07D 215/04* (2006.01),
C07D 215/14 (2006.01), *C07D 215/18* (2006.01),
C07D 401/00 (2006.01), *C07D 401/06* (2006.01),
C07D 405/04 (2006.01), *C07D 413/02* (2006.01),
C07D 417/02 (2006.01), *C07D 521/00* (2006.01)

(72) Inventeurs/Inventors:
WILHELM, ROBERT STEPHEN, US;
FATHEREE, PAUL ROSS, US;
CHIN, RONNIE LIPP, US

(73) Propriétaire/Owner:
SYNTEX (U.S.A.) INC., US

(74) Agent: DENNISON ASSOCIATES

(54) Titre : QUINOLEINES EN TANT QU'INHIBITEURS DE LA PHOSPHODIESTERASE DE TYPE IV
(54) Title: QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS




Formula I

(57) Abrégé/Abstract:

Optionally 6,8-substituted quinolines of formula (I) wherein: R¹ is selected from hydrogen; lower alkyl; cycloalkyl; cycloalkyloxy; cycloalkylamino; cycloalkyl lower alkyl; lower alkoxy; formyl; hydroxy-lower alkyl; carboxyalkyl; optionally substituted aryl, aryloxy, arylamino or aryl lower alkyl; optionally substituted heterocycle, heterocycle-oxy, heterocycle-amino or heterocycle lower alkyl; and R² is optionally substituted phenyl, or a pharmaceutically acceptable salt or N-oxide thereof, useful as anti-inflammatory agents, immunosuppressive agents, anti-allograft rejection agents, anti-graft-vs-host disease agents, anti-allergic agents (e.g., asthma, rhinitis and atopic dermatitis), bronchodilation agents, anti-autoimmune agents or analgetic agents.



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : C07D 401/06, A61K 31/47, C07D 215/06, 215/12, 215/14, 405/04, 401/04		A1	(11) International Publication Number: WO 94/22852 (43) International Publication Date: 13 October 1994 (13.10.94)
(21) International Application Number: PCT/US94/03004 (22) International Filing Date: 23 March 1994 (23.03.94) (30) Priority Data: 08/040,731 31 March 1993 (31.03.93) US (71) Applicant: SYNTEX (U.S.A.) INC. [US/US]; 3401 Hillview Avenue, Palo Alto, CA 94304 (US). (72) Inventors: WILHELM, Robert, Stephen; 1438 Todd Street, Mountain View, CA 94040 (US). FATHEREE, Paul, Ross; 119 Parnassus, San Francisco, CA 94117 (US). CHIN, Ronnie, Lipp; 1746 Rock Street, Mountain View, CA 94043 (US). (74) Agents: KURZ, Walter et al.; Syntex (U.S.A.) Inc., 3401 Hillview Avenue, A2-200, Palo Alto, CA 94304 (US).		(81) Designated States: AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, ES, FI, GB, GE, HU, JP, KP, KR, KZ, LK, LU, LV, MG, MN, MW, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i> 2159603	
(54) Title: QUINOLINES AS TYPE IV PHOSPHODIESTERASE INHIBITORS			
 (I)			
(57) Abstract Optionally 6,8-substituted quinolines of formula (I) wherein: R ¹ is selected from hydrogen; lower alkyl; cycloalkyl; cycloalkyloxy; cycloalkylamino; cycloalkyl lower alkyl; lower alkoxy; formyl; hydroxy-lower alkyl; carboxyalkyl; optionally substituted aryl, aryloxy, arylamino or aryl lower alkyl; optionally substituted heterocycle, heterocycle-oxy, heterocycle-amino or heterocycle lower alkyl; and R ² is optionally substituted phenyl, or a pharmaceutically acceptable salt or N-oxide thereof, useful as anti-inflammatory agents, immunosuppressive agents, anti-allograft rejection agents, anti-graft-vs-host disease agents, anti-allergic agents (e.g., asthma, rhinitis and atopic dermatitis), bronchodilation agents, anti-autoimmune agents or analgetic agents.			

5

10

Quinolines as type IV phosphodiesterase inhibitors

BACKGROUND OF THE INVENTION

FIELD OF THE INVENTION

15

20

This invention relates to optionally 6,8-substituted quinolines useful as anti-inflammatory agents, immunosuppressive agents, anti-allograft rejection agents, anti-graft-vs-host disease agents, anti-allergic agents (e.g., asthma, rhinitis and atopic dermatitis), broncho-dilation agents, anti-autoimmune agents or analgetic agents, to their precursors, to their preparation and to pharmaceutical compositions using the compounds of the invention.

BACKGROUND INFORMATION

25

30

35

Cyclic 3',5'-adenosine monophosphate (cAMP) modulates a variety of cellular and physiologic functions in mammals, such as, cell division, endocrine function, and the immune response. The level of cAMP is controlled by a class of enzymes called phosphodiesterases, which enzymatically deactivate cAMP. There are five general types of phosphodiesterases, which are categorized according to their function and the type of cell from which they are isolated. For instance, high-affinity phosphodiesterase (PDE III) is isolated from human platelet cells and modulates platelet aggregation. Another type of phosphodiesterase (PDE IV) is found in various tissues but is the predominant form in human leukocytes; this enzyme modulates leukocyte activation and function associated with the immune response and inflammation. Both of these phosphodiesterases implement their control by modulating the cellular level of cAMP in their respective cells. Thus, inhibition of phosphodiesterases provides a method of modulating any cellular and bodily function that is controlled by cAMP.

40

45

Compounds that are nonspecific phosphodiesterase inhibitors are known, i.e., these compounds inhibit all or multiple types of phosphodiesterases. [See, Beavo, J.A. and D.H. Reifsyder, *Trends in Pharm. Science*, 11:150-155 (1990); and Nicholson, C.D., R.A.J. Challiss and M. Shahid, *Trends in Pharm. Science*, 12:19-27 (1991).] Since cAMP is involved in so many functions throughout the body, a nonspecific phosphodiesterase inhibitor has the potential to alter all of the functions modulated by cAMP, thus nonspecific phosphodiesterase inhibitors are of limited value because of numerous side-effects.

It has been surprisingly discovered that certain optionally substituted 6,8-quinolines are potent selective inhibitors of

2159603


-2-

Phosphodiesterase Type IV (PDE IV). These compounds are well suited for use as a treatment for any disorder in which PDE IV function plays a role, such as where leukocyte activation or function is involved.

In particular, these compounds are especially well suited for use as anti-inflammatory agents, immunosuppressive agents, anti-allograft rejection agents, anti-graft-vs-host disease agents, anti-allergic agents (e.g., asthma, rhinitis and atopic dermatitis), bronchodilation agents, anti-autoimmune disease agents or analgetic agents.

SUMMARY OF THE INVENTION

One aspect of the present invention relates to optionally substituted 6,8-quinolines, i.e., a compound of Formula I:



Formula I

wherein:

R¹ is selected from hydrogen; lower alkyl; cycloalkyl; cycloalkyloxy; cycloalkylamino; cycloalkyl lower alkyl; lower alkoxy; formyl; hydroxy-lower alkyl; carboxyalkyl; optionally substituted aryl, aryloxy, arylamino or aryl lower alkyl; optionally substituted heterocycle, heterocycle-oxy, heterocycle-amino or heterocycle lower alkyl; and

R² is optionally substituted phenyl,

or a pharmaceutically acceptable salt or N-oxide thereof.

Preferred aspects of R¹ are pyridylmethyl, benzyl, cycloalkylmethyl and lower alkyl.

In another aspect, the invention relates to a pharmaceutical composition containing a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or N-oxide thereof admixed with at least one pharmaceutically acceptable excipient.

In still another aspect, the invention relates to a method of use as an anti-inflammatory agent, immunosuppressive agent, anti-allograft rejection agent, anti-graft-vs-host disease agent, anti-allergic agent (e.g., asthma, rhinitis and atopic dermatitis), bronchodilation agents,

anti-autoimmune disease agent or analgetic agent, by administering to a mammal in need of such treatment a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or N-oxide thereof.

5 Yet another aspect of the invention relates to the treatment of the above conditions or diseases by the selective inhibition of PDE IV.

In another aspect, this invention provides compositions useful in the treatment of inflammatory, allograft rejection, graft-vs-host disease, allergy, autoimmune or analgetic conditions or diseases in mammals
10 comprising a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt or N-oxide as described above and a pharmaceutically acceptable excipient.

Another aspect of the invention relates to processes for making the compounds of Formula I and the pharmaceutically acceptable salts and N-oxides thereof.
15

DETAILED DESCRIPTION

20 DEFINITIONS AND GENERAL PARAMETERS

The following definitions are set forth to illustrate and define the meaning and scope of the various terms used to describe the invention herein.

25 The term "alkyl" refers to a branched or straight chain monovalent saturated aliphatic hydrocarbon radical of one to twenty carbon atoms.

The term "lower alkyl" refers to a branched or straight chain monovalent alkyl radical of one to four carbon atoms. This term is further exemplified by such radicals as methyl, ethyl, n-propyl, isopropyl, i-butyl, n-butyl and t-butyl.

30 The term "cycloalkyl" refers to a monovalent carbocyclic radical of three to six carbon atoms, i.e., cyclopropyl, cyclobutyl, cyclopentyl and cyclohexyl, which can optionally be substituted, independently, with, e.g., hydroxy, amino, imino, lower alkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, carbamoyl, acyl, aryl, halo, and/or cyano.

35 The term "cycloalkyloxy" refers to a cycloalkyl group attached to a parent structure via an oxy radical, i.e., -O-, such as cyclopentyloxy.

The term "cycloalkylamino" refers to a cycloalkyl group attached to a parent structure via an imino radical, i.e., -NH-, such as cyclopropylamino.

40 The term "cycloalkyl lower alkyl" refers to a cycloalkyl group attached to a parent structure via a lower alkylene group such as methylene; e.g., cyclopropylmethyl, cyclopentylethyl, cyclopentylpropyl, or cyclopentylmethyl.

45 The term "lower alkylene" refers to a biradical branched or unbranched saturated hydrocarbon chain containing 1 to 4 carbon atoms, such

2159603

-4-

as methylene (-CH₂-), ethylene, propylene, isopropylene and butylene.

The term "lower alkoxy" refers to the group -O-R' where R' is lower alkyl.

The term "carbonyl" refers to the group -C(O)-.

5 The term "carboxy" refers to the group -C(O)OH.

The term "carboxyalkyl" refers to the group -alkyl-C(O)OH, where alkyl is a branched or straight chain monovalent alkyl radical of one to eight carbon atoms.

10 The term "lower alkoxycarbonyl" refers to the group -C(O)OR' where R' is lower alkyl.

The term "acyl" refers to the group -C(O)-R', where R' is lower alkyl, e.g., acetyl or propionyl; or optionally substituted phenyl or heterocycle, e.g., phenacyl.

15 The term "carbamoyl" refers to the group -C(O)NR'R where R and R' are independently hydrogen or lower alkyl, e.g., where R is hydrogen and R' is lower-alkyl the group is lower alkylcarbamoyl, where R and R' are lower alkyl the group is di-lower alkylcarbamoyl.

The term "halo" refers to fluoro, bromo, chloro and iodo.

The term "lower alkylthio" refers to the group R-S-.

20 The term "lower alkylsulfinyl" refers to the group R-S(O)-.

The term "lower alkylsulfonyl" refers to the group R-S(O)₂-.

The term "lower alkoxysulfonyl" refers to the group RO-S(O)₂-.

The term "hydroxysulfonyl" refers to the group HO-S(O)₂-.

25 The term "aryl" refers to a monovalent carbocyclic aromatic radical (e.g., phenyl), or two condensed carbocyclic rings (e.g., naphthyl) which can optionally be mono-, di-, or tri-substituted, independently, with hydroxy, thiol, amino, halo, nitro, lower alkyl, lower alkylthio, lower alkoxy, mono-lower alkylamino, di-lower alkylamino, carboxy, lower alkoxycarbonyl, hydroxysulfonyl, lower alkoxysulfonyl, lower alkylsulfonyl, 30 lower alkylsulfinyl, trifluoromethyl, cyano, tetrazolyl, carbamoyl, lower alkylcarbamoyl, and di-lower alkylcarbamoyl.

The term "aryloxy" refers to an aryl group as defined above attached to a parent structure via an oxy radical, i.e., aryl-O-.

35 The term "arylamino" refers to an aryl group as defined above attached to a parent structure via an imino radical, i.e., aryl-NH-.

The term "aryl lower alkyl" refers to an aryl group attached to a parent structure via a lower alkylene group such as methylene; e.g., benzyl.

40 The term "heterocycle" refers to a saturated, unsaturated or aromatic monovalent cyclic radical having at least one hetero atom (such as nitrogen, oxygen or sulfur) or a combination thereof, which can optionally be substituted, independently, with, e.g., hydroxy, amino, imino, lower alkyl, lower alkoxy, carboxy, lower alkoxycarbonyl, carbamoyl, acyl, aryl, halo, and/or cyano. Further, the term also includes instances where an atom


of a heterocycle has been oxidized, e.g., N-oxides, sulfoxides, sulfones, or oxo. For example, typical heterocycles with one or more nitrogen or sulfur atoms are pyrrole, imidazole, imidazoline, imidazolidine, pyrazole, pyrazine, pyrrolidine, pyrrolidinone, pyrazolidine, piperidine, piperazine, morpholine, pyridine, pyridone, triazole, oxazole, oxadiazole, thiazole, and the like.

The term "heterocycle-oxy" refers to a heterocyclic group as defined above attached to a parent structure via an oxy radical, i.e., heterocycle-O-.

The term "heterocycle-amino" refers to a heterocyclic group as defined above attached to a parent structure via an imino radical, i.e., heterocycle-NH-.

The term "heterocycle lower alkyl" refers to a heterocyclic group attached to a parent structure via a lower alkylene group such as methylene (-CH₂-); e.g., 4-pyridylmethyl.

The term "tetrazolyl" refers to the group



The term "optionally substituted phenyl" refers to phenyl and mono-, di-, tri- or tetra-substituted phenyl, wherein the optional substituents are lower alkyl, hydroxy, thiol, amino, halo, nitro, cyano, lower alkoxy, lower alkylthio, mono-lower alkylamino, di-lower-alkylamino, carboxy, lower alkoxy-carbonyl, lower alkylene-dioxy, hydroxysulfonyl, lower alkoxy-sulfonyl, lower alkylsulfonyl, lower-alkylsulfinyl, trifluoromethyl, trifluoromethyloxy, tetrazolyl, carbamoyl, lower alkylcarbamoyl, and di-lower alkylcarbamoyl. This term is further exemplified by such radicals as 3-chlorophenyl, 3-nitrophenyl, 4-methoxyphenyl, 3-cyanophenyl, 4-trifluorophenyl, 3-chloro-4-fluorophenyl and 3,4-methylenedioxyphenyl.

The term "N-oxide" refers to nitrogen heterocycles where a nitrogen atom in the ring has been oxidized, e.g., 4-pyridyl-N-oxide, 3-pyridyl-N-oxide, or 2-pyridyl-N-oxide.

The term "hydroxy-lower alkyl" refers to a lower alkyl radical substituted with a hydroxy group, e.g., -CH(OH)CH₂CH₃ or -C(OH)(CH₃)₂.

The term "pharmaceutically acceptable salt" refers to any salt derived from an inorganic or organic acid or base.

The term "pharmaceutically acceptable anion" refers to the anion of such acid addition salts. The term "pharmaceutically acceptable cation" refers to the cation of such base addition salts. The salt, anion and/or the cation are chosen not to be biologically or otherwise undesirable. The anions are derived from inorganic acids, such as hydrochloric acid, hydrobromic acid, sulfuric acid (giving the sulfate and bisulfate salts), nitric acid, phosphoric acid and the like, and organic acids such as acetic

acid, propionic acid, glycolic acid, pyruvic acid, oxalic acid, malic acid, malonic acid, succinic acid, maleic acid, fumaric acid, tartaric acid, citric acid, benzoic acid, cinnamic acid, mandelic acid, methanesulfonic acid, ethanesulfonic acid, salicylic acid, p-toluenesulfonic acid and the like.

The cations are derived from bases, such as alkaline earth hydroxides, including calcium hydroxide, potassium hydroxide, sodium hydroxide, lithium hydroxide and the like.

As used herein, the term "allograft rejection" refers to the humoral or cellular immune response mounted by the immune system of a mammal after it has received a histo-incompatible tissue graft from another mammal of the same species, thereby producing tissue injury to the graft in such a recipient.

As used herein, the term "graft-vs-host disease" refers to the immune response that originates from transplanted graft tissue, in particular, transplanted bone-marrow tissue, and that is directed towards the host tissue, thereby producing tissue injury in the host.

As used herein, the term "autoimmune disease" refers to disorders wherein the immune system of a mammal mounts a humoral or cellular immune response to the mammal's own tissue or to antigenic agents that are not intrinsically harmful to the mammal, thereby producing tissue injury in such a mammal. Examples of such disorders include, but are not limited to, systemic lupus erythematosus, rheumatoid arthritis and type I diabetes.

As used herein, the terms "treatment" or "treating" of a condition and/or a disease in a mammal, means:

(i) preventing the condition or disease, that is, avoiding any clinical symptoms of the disease;

(ii) inhibiting the condition or disease, that is, arresting the development or progression of clinical symptoms; and/or

(iii) relieving the condition or disease, that is, causing the regression of clinical symptoms.

The conditions and diseases treated in the present invention include inflammation, pain, pyrexia, autoimmune disease, allograft rejection, graft-vs-host disease, allergies and uveitis.

As used herein, the term "therapeutically effective amount" refers to that amount of a compound of Formula I which, when administered to a mammal in need thereof, is sufficient to effect treatment (as defined above) as an anti-inflammatory agent, immunosuppressive agent, anti-allograft rejection agent, anti-graft-vs-host disease agent, anti-allergy agent, autoimmune disease agent or analgetic agent. The amount that constitutes a "therapeutically effective amount" will vary depending on the compound, the condition or disease and its severity, and the mammal to be treated, but may be determined routinely by one of ordinary skill in the art with regard to contemporary knowledge and to this disclosure.

As used herein, the term "q.s." means adding a quantity sufficient to


achieve a stated function, e.g., to bring a solution to a desired volume (e.g., 100 mL).

As used herein, the term "mp" refers to melting point. All temperatures are given in degrees Celsius (°C).

Unless specified to the contrary, the reactions described herein take place at atmospheric pressure over a temperature range from about -78°C to about 150°C, more preferably from about 10°C to about 50°C, and most preferably at about room (or "ambient") temperature, e.g., about 20°C. Unless specified to the contrary, the ranges of time and temperature described herein are approximate, e.g., "from 8 to 24 hours at from 10°C to 100°C" means from about 8 to about 24 hours at about 10°C to about 100°C.

Isolation and purification of the compounds and intermediates described herein can be effected, if desired, by any suitable separation or purification procedure such as, for example, filtration, extraction, crystallization, column chromatography, preparative high pressure liquid chromatography (preparative HPLC), thin-layer chromatography or thick-layer chromatography, or a combination of these procedures. Specific illustrations of suitable separation and isolation procedures can be had by reference to the examples hereinbelow. However, other equivalent separation or isolation procedures can also be used.

The following numbering and nomenclature system will be used for naming the compounds of the invention.



E.g., the compound of Formula I where R¹ is 4-pyridylmethyl and R² is 3-chloro-4-fluorophenyl can be named 6-(4-pyridylmethyl)-8-(3-chloro-4-fluorophenyl)quinoline.

The compound of Formula I where R¹ is isopropyl and R² is 4-chlorophenyl can be named 6-(isopropyl)-8-(4-chlorophenyl)quinoline.

SYNTHESIS OF THE COMPOUNDS OF FORMULA I

As used in the Reaction Schemes R¹ and R² are the same as described in the Summary of the Invention.

Reaction Scheme A illustrates the preparation of 6,8-(disubstituted) quinolines, i.e., the compounds of Formula I.

Reaction Scheme A-1 illustrates the preparation of intermediates

of formula 3a which can be converted into compounds of formula I where R¹ is cycloalkylmethyl, arylmethyl or heterocycle-methyl by following the reactions as shown in Reaction Scheme A.

Reaction Scheme B illustrates an alternate preparation of 6,8-(disubstituted) quinolines, i.e., the compounds of Formula I, where the final two steps in Reaction Scheme A are carried out in reverse order.

Reaction Scheme B-1 illustrates an alternate preparation of 6,8-(disubstituted) quinolines, i.e., the compounds of Formula I, via the 8-ZnCl-quinoline intermediate.

Reaction Scheme B-2 illustrates the preparation of 6-substituted-8-haloquinolines, in particular, the compounds of Formula 5 where X is halo and R¹ is cycloalkylaminomethyl, arylaminomethyl, heterocycle-aminomethyl or heterocycle-methyl, i.e., where the methylene group is attached to a nitrogen atom of a heterocycle.


Reaction Scheme B-3 illustrates the preparation of 6,8-(disubstituted) quinolines, in particular, the compounds of Formula I where R¹ is cycloalkyloxy, aryloxy or heterocycle-oxy.

Reaction Scheme C illustrates the preparation of 6-[lower alkyl-(hydroxy)methyl]-8-quinolines, and 6-formyl-8-quinolines, i.e., the compounds of Formula I where R¹ is formyl, or lower alkyl-(hydroxy)methyl.


Reaction Schemes C-1 and C-2 illustrate alternate preparations of 6,8-(disubstituted)quinolines, in particular, the compounds of Formula I where R¹ is alkyl, cycloalkylmethyl, cycloalkenylmethyl, arylmethyl or heterocycle-methyl.

Reaction Scheme C-3 illustrates an alternate preparation of 6,8-(disubstituted)quinolines, in particular, the compounds of Formula I where R¹ is mono- or di-alkylaminomethyl, cycloalkylaminomethyl, arylaminomethyl, heterocycle-aminomethyl or heterocycle-methyl, i.e., where the methylene group is attached to a nitrogen atom of a heterocycle.


REACTION SCHEME A



where X is chloro,
bromo or iodo




where R^2 is optionally substituted phenyl



Formula 1

REACTION SCHEME A-1



where R is alkyl, cycloalkyl, aryl lower alkyl or heterocycle lower alkyl

where X is chloro or bromo

STARTING MATERIALS

Referring to the Reaction Schemes, the compounds of Formula 1 (i.e., 4-optionally substituted nitrobenzene) and Formula 2 (i.e., 4-optionally substituted aniline) are commercially available from Aldrich Chemicals Co., Inc., Fluka Chemical Corporation, Lancaster Synthesis Ltd., Karl Industries, Maybridge Chemical Co. Ltd. or Tokyo Kasai International. The compounds of Formula 3A, i.e., optionally substituted benzene boronic acid, are commercially available from Lancaster Synthesis Ltd., or alternatively can be prepared following the procedures in Organic Synthesis, Coll Vol 4.

2159603

-10-

Those compounds that are not commercially available can be prepared by one of ordinary skill in the art following procedures set forth in references such as, "Fieser and Fieser's Reagents for Organic Synthesis", Volumes 1-15, John Wiley and Sons, 1991; "Rodd's Chemistry of Carbon Compounds", Volumes 1-5 and Supplementals, Elsevier Science Publishers, 1989; and "Organic Reactions", Volumes 1-40, John Wiley and Sons, 1991.

PREPARATION OF FORMULA 2

An optionally substituted p-nitrobenzene is combined with about 5 molar equivalents of a reducing agent, such as $\text{SnCl}_2 \cdot \text{H}_2\text{O}$, Fe/acetic acid, or palladium on carbon/ H_2 , preferably $\text{SnCl}_2 \cdot \text{H}_2\text{O}$, in a solvent such as ethanol, or ethyl acetate, preferably ethanol. The solution is heated. The temperature and duration will vary according to the reagent and solvent used, e.g., using ethanol and $\text{SnCl}_2 \cdot \text{H}_2\text{O}$, the solution is heated at a temperature in the range of about 50°C to 90°C, preferably about 70°C, for a period of about 1 hour to 3 hours, preferably about 2 hours. The progress of the reaction is monitored by TLC (thin layer chromatography). When the reaction is substantially complete, the product is isolated and purified by conventional means yielding the desired optionally substituted p-aminobenzene compound (i.e., a compound of Formula 2).

PREPARATION OF FORMULA 3

A solution of about 1 molar equivalent of a halogenating agent, such as N-bromosuccinimide (NBS), or N-chlorosuccinimide (NCS), preferably N-bromosuccinimide, in a solvent, preferably DMF is added in a gradual manner to a solution of an optionally substituted p-aminobenzene compound (Formula 2) dissolved in a solvent (such as DMF, preferably DMF). The reaction mixture is stirred at about room temperature for a period of about 1 to 5 hours, preferably about 3 hours. When the reaction is substantially complete (by TLC), the product is isolated and purified by conventional means yielding the desired optionally substituted p-amino-m-halobenzene compound (i.e., a compound of Formula 3 where X is chloro or bromo).

PREPARATION OF FORMULA 4

An optionally substituted p-amino-m-halobenzene compound (Formula 3) is combined with about 1 to 5 molar equivalent, preferably about 2 molar equivalent, of an optionally substituted benzene boronic acid, i.e., Formula 3B where R^2 is optionally substituted phenyl, 2 M Na_2CO_3 (about 4 molar equivalent), methanol or ethanol, preferably ethanol, and benzene or toluene, preferably benzene. To this solution is added about 0.01 to 0.1 molar equivalent, preferably about 0.035 molar equivalent, of palladium tetrakis triphenylphosphine. The reaction mixture is heated at about reflux for a period of about 3 to 9 hours, preferably about 6 hours. When the reaction is substantially complete (by TLC), the product is isolated

2159603


-11-

and purified by conventional means yielding the desired optionally substituted *p*-amino-*m*-arylbenzene compound (e.g., a compound of Formula 4).


PREPARATION OF FORMULA I

An optionally substituted *p*-amino-*m*-arylbenzene compound (Formula 4) is combined with about 1 molar equivalent of an oxidant, such as ferric oxide, *m*-nitrobenzenesulphonic acid, nitrobenzene, iron(II) sulfate (heptahydrate)/nitrobenzene or arsenic pentoxide, preferably arsenic pentoxide, and 3 molar equivalent of glycerol under an inert atmosphere. The mixture is heated at a temperature in the range of about 75°C to 125°C, preferably about 100°C, for a period of about 15 minutes to 45 minutes, preferably about 30 minutes. About 12 molar equivalent of a concentrated acid (preferably concentrated H₂SO₄) is added to the mixture in a gradual manner, and the mixture is heated at a temperature in the range of about 100°C to 200°C, preferably about 150°C for a period of about 1 to 3 hours, preferably about 2 hours. The progress of the reaction is monitored by TLC (9:1 hexane:ethyl acetate). When the reaction is substantially complete (by TLC), the product is isolated and purified by conventional means yielding the desired 6-optionally substituted-8-arylquinoline compound (i.e., a compound of Formula I).


REACTION SCHEME B



where X is chloro,
bromo or iodo



REACTION SCHEME B-1




10

where X is chloro,
bromo or iodo

where R² is
optionally substituted phenyl

REACTION SCHEME B-2




25


where X is
chloro,
bromo, or
iodo

where R is lower
alkyl, cycloalkyl,
aryl or hetero-
cycle

where R₂ is
independently
lower alkyl or aryl;
or NR₂ is heterocycle

REACTION SCHEME B-3





where R is lower alkyl,
cycloalkyl, aryl or heterocycle,
and X is chloro, bromo or iodo

PREPARATION OF FORMULA 5

An optionally substituted p-amino-m-halobenzene compound (Formula 3) combined with about 1 molar equivalent of arsenic pentoxide and 3 molar equivalent of glycerol under an inert atmosphere. The mixture is heated at a temperature in the range of about 75°C to 125°C, preferably about 100°C, for a period of about 15 minutes to 45 minutes, preferably about 30 minutes. About 12 molar equivalent of a concentrated acid (preferably concentrated H₂SO₄) is added to the mixture in a gradual manner, and the mixture is heated at a temperature in the range of about 100°C to 200°C, preferably about 150°C for a period of about 1 to 3 hours, preferably about 2 hours. When the reaction is substantially complete (by TLC), the product is isolated and purified by conventional means yielding the desired 6-optionally substituted-8-haloquinoline compound (i.e., a compound of Formula 5).

PREPARATION OF FORMULA 3B

About 2 molar equivalents of trimethylborate is dissolved in an apolar solvent (such as diethyl ether, or tetrahydrofuran, preferably diethyl ether) and cooled at a temperature in the range of about -50 to -80°C, preferably about -65°C.

An optionally substituted phenyl Grignard reagent is added to the solution in a gradual (e.g., dropwise) manner over a period of about 20 minutes/molar equivalent. The mixture is then stirred at a temperature in the range of about -50°C to -80°C for about 15 to 45 minutes, preferably about 30 minutes. The mixture is allowed to warm to about -10°C to 10°C, preferably about 0°C and stirred for a period of about 1 hour. Water is added to the reaction mixture and the mixture is stirred for a period of about 1 hour. The organic layer is removed and the residue is extracted (e.g., 3 x ethyl acetate).

The organic layers are combined and dried over a drying agent (e.g., MgSO₄). The solution is concentrated, hexanes are added to the solution and the solution is stirred for a period of about 1 hour until a free flowing suspension forms. The suspension is filtered and air dried. The resultant optionally substituted benzene boronic acid (i.e., a compound of Formula

3B) is carried on to the next step of the process.


PREPARATION OF FORMULA 3C

An optionally substituted phenol is dissolved in an aprotic solvent (such as CH_2Cl_2 or THF, preferably CH_2Cl_2) and cooled to 0 C. About 5 molar equivalents of triethylamine are added, followed by about 1.5 molar equivalents of trifluoromethanesulfonic anhydride (triflic anhydride) (e.g., via addition funnel) under nitrogen over a period of 15 min to 60 min, preferably 30 min. The solution is poured into a saturated NaHCO_3 solution and extracted with an aprotic solvent such as CH_2Cl_2 . The organic layer is washed with water (2 x), and brine (100 mL), dried over a drying agent (e.g., MgSO_4), filtered, and concentrated. Flash chromatography using 10-50%, preferably 20%, ethyl acetate/hexanes provides a slightly impure brown oil which can be distilled under vacuum to give the trifluoromethanesulfonyloxy derivative (triflate) as a yellow liquid.

PREPARATION OF FORMULA I



An 6-optionally substituted-8-haloquinoline compound (i.e., a compound of Formula 5) is combined with about 2 molar equivalent of an optionally substituted benzene boronic acid, i.e., Formula 3A, 2 M Na_2CO_3 (about 4 molar equivalent), methanol, and benzene. To this solution is added about 0.1 molar equivalent of palladium tetrakis triphenylphosphine. The reaction mixture is heated at about reflux for a period of about 3 to 9 hours, preferably about 6 hours. The progress of the reaction is monitored by TLC. Upon completion of the reaction, the mixture is allowed to cool to about room temperature, and the solvents are removed. About 40 mL/molar equivalent of ethyl acetate is added to the residue and filtered through a drying agent (e.g., Na_2SO_4). The product is isolated by chromatography, preferably preparative thin layer chromatography, yielding the desired 6-optionally substituted-8-aryl-quinoline compound (i.e., a compound of Formula I).

REACTION SCHEME C




where R^2 is optionally substituted phenyl

where X is chloro, bromo or iodo



REACTION SCHEME C-1




where X is chloro,
bromo or iodo

where R is cycloalkenyl,
aryl or heterocycle

2159603


-16-

REACTION SCHEME C-2



10 where X is chloro,
bromo or iodo

where R is alkyl,
cycloalkyl,
or heterocycle




Formula I

25 where R² is optionally
substituted phenyl

where R is alkyl,
cycloalkyl or heterocycle

REACTION SCHEME C-3



35 where X is
chloro or
bromo

where R is lower
alkyl, cycloalkyl,
aryl or hetero-
cycle

where R₂ is
independently
lower alkyl or aryl;
or NR₂ is heterocycle

PREPARATION OF FORMULA I WHERE R¹ IS -CH₂-X AND/OR -CH-X₂

45 A 6-methyl-8-optionally substituted phenyl-quinoline (i.e., a
compound of Formula I where R¹ is methyl, prepared according procedures
described in Reaction Scheme A or B) is dissolved in a solvent such as

2159603

carbon tetrachloride and heated under reflux. About 1 molar equivalent of a halogenating reagent, such as N-bromosuccinamide (NBS) or N-chlorosuccinamide (NCS), preferably N-bromosuccinamide and about 0.2 molar equivalent of 2,2'-azobis(2-methylpropionitrile) are added to the refluxing solution. The reaction mixture is optionally exposed to light (e.g., 250 W light bulb) for a period of about 30 minutes to 90 minutes, preferably about 1 hour. The reaction mixture is then stirred for a period of about 1 to 3 hours, preferably about 2 hours. The progress of the reaction is monitored by TLC. Upon conversion of greater than about 90% of the starting material, the reaction solution is cooled to about 0°C, then poured through a drying agent, such as Na₂SO₄. The solution is concentrated yielding the mono- and di-halogenated products (i.e., Formula I, where R¹ is CH₂-X and -CH-X₂) which are taken on to the next step without further purification or isolation.

PREPARATION OF FORMULA I WHERE R¹ IS FORMYL

The mono and dihalogenated quinoline mixture from the previous step is dissolved in a solvent, such as methylene chloride or chloroform, preferably chloroform, and added in a gradual manner to an oxidizing reagent, such as about 5 molar equivalents of tetra n-butylammonium dichromate in a solvent, such as methylene chloride or chloroform, preferably chloroform. The reaction mixture is heated, preferably at reflux temperature, and refluxed for about 2 to 6 hours, preferably about 4 hours. The reaction mixture is allowed to cooled to about room temperature and filtered, preferably through a silica gel pad. The residue is eluted with an ether, preferably diethyl ether, and isolated and purified by chromatography to obtain the desired 6-formyl-8-(optionally substituted phenyl)quinoline (i.e., Formula I where R¹ is formyl). Alternatively, the mono and di-halogenated quinoline mixture can be oxidized by the Kornblum oxidation [Chem Rev, Vol 67, No. 3, (1967), p 247-260] or the Sommelet oxidation [Org. React., Vol 8, p 197-217 (1954)].

PREPARATION OF FORMULA I WHERE R¹ IS -CH(OH)-(LOWER ALKYL)

A 6-formyl-8-(optionally substituted phenyl)quinoline is dissolved in a nonpolar solvent, preferably tetrahydrofuran, and cooled to a temperature in the range of about -50°C to -100°C, preferably about -78°C. To this solution is added an alkylation reagent, such as a lower-alkyl Grignard reagent, or a lower-alkyl lithium reagent (about 1 to 3 molar equivalent, preferably about 2 molar equivalent) in a gradual manner. The reaction mixture is stirred for a period of about 10 to 30 minutes, preferably about 20 minutes. The reaction mixture is then quenched with an aqueous salt solution, preferably saturated ammonium chloride. The desired product is purified by extraction (preferably with ethyl acetate), and drying (preferably over MgSO₄). The residue is further purified and isolated by

chromatography to yield the desired optionally substituted 6-[(lower alkyl(hydroxy)methyl)-8-(optionally substituted phenyl)quinoline, i.e., Formula I where R¹ is lower alkyl (hydroxy)methyl.

5 **PREPARATION OF THE SALT OF FORMULA I**

The pharmaceutically acceptable salts of Formula I are prepared by dissolving a compound of Formula I in a suitable solvent (such as methanol, dioxane or diethyl ether) adding 1 to 3 molar equivalents (preferably about two molar equivalent) of an appropriate acid (such as hydrogen chloride

10 gas) or base (such as an alkaline earth hydroxide, e.g., lithium hydroxide, calcium hydroxide, potassium hydroxide, sodium hydroxide or the like; preferably sodium hydroxide) and stirring.

The salt is isolated by lyophilization or by precipitation, using techniques that will be apparent to those skilled in the art.

15 **PREPARATION OF N-OXIDES OF FORMULA I**

A compound of Formula I, where R¹ is pyridylmethyl (e.g., 4-pyridylmethyl, 3-pyridylmethyl or 2-pyridylmethyl), is converted to the corresponding N-oxide derivative by treating it with an oxidizing agent

20 (e.g., *m*-chloroperoxybenzoic acid) in a solvent (e.g., methylene chloride). The solution is stirred for a period of about 30 to 90 minutes, preferably about 60 minutes at a temperature in the range of about 0°C to 50°C, preferably about room temperature. Following the reaction, the desired product is isolated and purified by preparative thin-layer chromatography.

25 **PREFERRED COMPOUNDS**

Presently preferred are the compounds of Formula I where R² is 3-chlorophenyl, 3-nitrophenyl, 3-cyanophenyl or 3-chloro-4-fluoro-phenyl.

Of the compounds where R² is 3-chlorophenyl, 3-nitrophenyl or 3-cyanophenyl most preferred are the compounds of Formula I where and R¹ is

30 4-pyridylmethyl, benzyl, ethyl, *n*-propyl, isopropyl, *n*-butyl or 1-hydroxy-1-methylethyl.

Of the compounds where R² is 3-chloro-4-fluorophenyl most preferred are the compounds of Formula I where R¹ is 4-pyridylmethyl, benzyl, ethyl,

35 *n*-propyl, isopropyl, *n*-butyl or 1-hydroxy-1-methylethyl.

PREFERRED PROCESSES

A preferred process for making 6-optionally substituted 8-aryl-quinolines is combining the corresponding optionally substituted benzene

40 boronic acid with the corresponding 6-optionally substituted quinoline.

Another preferred process for making 6-optionally substituted 8-aryl-quinolines is combining the corresponding optionally substituted *p*-amino-*m*-benzene with glycerol and arsenic pentoxide.


Other preferred processes for making 6-optionally substituted 8-aryl-

quinolines are shown in Reaction Schemes C, C-1, C-2, and C-3.

LAST STEPS

The compounds of this invention are prepared according to the following processes:

A process for the preparation of a compound of the formula



Formula I

wherein:


R¹ is selected from hydrogen; lower alkyl; cycloalkyl; cycloalkyloxy; cycloalkylamino; cycloalkyl lower alkyl; lower alkoxy; formyl; hydroxy-lower alkyl; carboxyalkyl; optionally substituted aryl, aryloxy, arylamino or aryl lower alkyl; optionally substituted heterocycle, heterocycle-oxy, heterocycle-amino or heterocycle lower alkyl; and

R² is optionally substituted phenyl,

provided that when R¹ is methoxy, R² is not 4-nitrophenyl or 4-aminophenyl;

or a pharmaceutically acceptable salt or N-oxide thereof, which comprises

(a) reacting a compound of the formula (4)




where

R¹ and R² are as defined above, with glycerol in the presence of an oxidant; or

2159603


-20-

(b) reacting a compound of the formula (5)




where

R^1 is as defined above and X is chloro, bromo or iodo, with a boronic acid of the formula (3B)



where R^2 is optionally substituted phenyl; or

(c) reacting a compound of the formula




where

R^1 is as defined above, with a trifluoromethanesulfonyloxy benzene of the formula (3C)




where R^2 is optionally substituted phenyl, and -OTf is trifluoromethanesulfonyloxy; or

(d) reacting a compound of the formula (5)




where

R is lower alkyl, cycloalkyl, aryl, or heterocycle, with a boronic acid of the formula (3B)



where R^2 is optionally substituted phenyl; or


(e) reacting a compound of the formula (I)



where

R^2 is optionally substituted phenyl, with a lower alkyl Grignard reagent or a lower alkyl lithium reagent; or

(f) reacting a compound of the formula




where

R^2 is optionally substituted phenyl, with a boronic acid of the formula (3B)



where R is cycloalkenyl, aryl or heterocycle; or


(g) reacting a compound of the formula



where

R^2 is optionally substituted phenyl, and R is alkyl, cycloalkyl or heterocycle, with a concentrated acid; or

(h) reacting a compound of the formula



where

R_2 is optionally substituted phenyl and X is chloro, bromo or iodo,

with a compound of the formula



where R is lower alkyl, cycloalkyl, aryl or heterocycle; and R₂ is independently lower alkyl or aryl; or NR₂ is heterocycle; or

(i) reacting the free base of a compound of Formula I with an acid to give a pharmaceutically acceptable acid addition salt; or

(j) reacting an acid addition salt of a compound of Formula I with a base to give the corresponding free base; or

(k) converting an acid addition salt of a compound of Formula I to another pharmaceutically acceptable acid addition salt of Formula I.

UTILITY, TESTING AND ADMINISTRATION

GENERAL UTILITY

The compounds of this invention, including the pharmaceutically acceptable salts and N-oxides thereof, and the compositions containing them are particularly useful as anti-inflammatory, immunosuppressive, anti-allograft rejection, anti-graft-vs-host disease, anti-allergic agents (e.g., asthma, rhinitis and atopic dermatitis), bronchodilation agents, anti-autoimmune disease or analgetic agents. The compounds of this invention act as PDE IV selective inhibitors, thereby modulating cAMP levels. Thus, these compounds are of use for the treatment of cAMP related conditions or diseases, particularly those that are modulated by leukocyte cAMP.

For example, inflammation, autoimmune diseases, graft-vs-host disease and allograft rejection are conditions that are manifested by the proliferation of lymphocytes. The proliferation is triggered by the presence of cAMP at specific levels. Inhibition of lymphocyte proliferation is accomplished by increasing levels of cAMP resulting from the inhibition of lymphocyte phosphodiesterase.

TESTING

Potency and selectivity of compounds as inhibitors of PDE IV is determined by following, for example, the procedures described in Example 22, or modifications thereof.

The immunomodulatory and anti-inflammatory activity of the compounds of the invention can be determined by a variety of assays utilizing both *in vitro* and *in vivo* procedures.

Inhibition of the proliferation of lymphocytes in response to mitogenic stimulation is determined by the procedures described by Greaves, et al. ["Activation of human T and B lymphocytes by polyclonal mitogens,"

Nature, 248, 698-701 (1974)], or modifications thereof (Example 23).

Inhibition of lymphocyte activation in response to antigenic challenge is determined *in vitro* by inhibition of a cytolytic T-cell assay (CTL) as described by Wunderlich, et al., Nature (1970), Vol. 228, p. 62, or a modification thereof.

Immune modulation is determined by *in vivo* procedures utilizing the Jerne Hemolytic Plaque Assay, [Jerne, et al., "The agar plaque technique for recognizing antibody producing cells," *Cell-bound Antibodies*, Amos, B. and Kaprowski, H. editors (Wistar Institute Press, Philadelphia) 1963, p. 109] or a modification thereof (Example 24).

Anti-inflammatory activity is determined by the Arachidonic Acid-Induced Mouse Ear Edema Assay [Young, et al., *J. Invest. Derm.*, 82: 367-371 (1984)] (Example 25).

Anti-inflammatory activity is also determined by the Adjuvant Arthritis assay [Pearson, C.M., *Proc. Soc. Exp. Biol. Med.*, 91:95-101 (1956)], or modifications thereof (Example 26).

Anti-autoimmune activity in treating autoimmune disease can be determined utilizing the survivability of MRL/lpr mice described by Theofilopoulos, et al., *Advances in Immunology*, Vol 37, pages 269-390 (1985) on pages 274-276, or a modification thereof (Example 27).

Analgetic activity is determined by the Phenylquinone-induced Mouse Writhing Assay [Hendershot, et al., *J. Pharmacol. Exp. Ther.*, 125: 237-240 (1959)] (Example 28).

ADMINISTRATION

The compounds of this invention are administered at a therapeutically effective dosage, i.e., that amount which, when administered to a mammal in need thereof, is sufficient to effect treatment, as described above (for example, to reduce or otherwise treat inflammation, pain and/or pyrexia in the mammal). Administration of the active compounds and salts described herein can be via any of the accepted modes of administration for agents that serve similar utilities.

The level of the drug in a formulation can vary within the full range employed by those skilled in the art, e.g., from about 0.01 percent weight (%w) to about 99.99%w of the drug based on the total formulation and about .01%w to 99.99%w excipient. Preferably the drug is present at a level of about 10%w to about 70%w.

Generally, an acceptable daily dose is of about 0.001 to 50 mg per kilogram body weight of the recipient per day, preferably about 0.05 to 25 mg per kilogram body weight per day, and most preferably about 0.01 to 10 mg per kilogram body weight per day. Thus, for administration to a 70 kg person, the dosage range would be about 0.07 mg to 3.5 g per day, preferably about 3.5mg to 1.75 g per day, and most preferably about 0.7 mg to 0.7 g per day depending upon the individuals and disease state being

treated. Such use optimization is well within the ambit of those of ordinary skill in the art.

Administration can be via any accepted systemic or local route, for example, via parenteral, oral (particularly for infant formulations), intravenous, nasal, bronchial inhalation (i.e., aerosol formulation), transdermal or topical routes, in the form of solid, semi-solid or liquid dosage forms, such as for example, tablets, suppositories, pills, capsules, powders, solutions, suspensions, aerosols, emulsions or the like, preferably in unit dosage forms suitable for simple administration of precise dosages. The compositions will include a conventional pharmaceutical carrier or excipient and an active compound of Formula I and, in addition, may include other medicinal agents, pharmaceutical agents, carriers, adjuvants, etc. Carriers can be selected from the various oils, including those of petroleum, animal, vegetable or synthetic origin, for example, peanut oil, soybean oil, mineral oil, sesame oil, and the like. Water, saline, aqueous dextrose, and glycols are preferred liquid carriers, particularly for injectable solutions. Suitable pharmaceutical carriers include starch, cellulose, talc, glucose, lactose, sucrose, gelatin, malt, rice, flour, chalk, silica gel, magnesium stearate, sodium stearate, glycerol monostearate, sodium chloride, dried skim milk, glycerol, propylene glycol, water, ethanol, and the like. Other suitable pharmaceutical carriers and their formulations are described in "Remington's Pharmaceutical Sciences" by E. W. Martin.

If desired, the pharmaceutical composition to be administered may also contain minor amounts of non-toxic auxiliary substances such as wetting or emulsifying agents, pH buffering agents and the like, such as for example, sodium acetate, sorbitan monolaurate, triethanolamine oleate, etc.

The compounds of this invention are generally administered as a pharmaceutical composition which comprises a pharmaceutical excipient in combination with a compound of Formula I. The level of the drug in a formulation can vary within the full range employed by those skilled in the art, e.g., from about .01 percent weight (%w) to about 99.99%w of the drug based on the total formulation and about .01%w to 99.99%w excipient. Preferably, the formulation will be about 3.5 to 60% by weight of the pharmaceutically active compound, with the rest being suitable pharmaceutical excipients.

INTRAVENOUS ADMINISTRATION

Intravenous injection has proven to be an important route of administration for therapeutic agents. The compounds of the present invention can be administered via this route, for example, by dissolving the compound, ester, ether, N-oxide or salt in a suitable solvent (such as water or saline) or incorporation in a liposomal formulation followed, by dispersal into an acceptable infusion fluid. A typical daily dose of a

compound of the invention can be administered by one infusion, or by a series of infusions spaced over periodic intervals.

ORAL ADMINISTRATION

5 Oral administration can be used to deliver the compound of Formula I using a convenient daily dosage regimen which can be adjusted according to the degree of affliction or for renal impairment, or to compensate for the toxic effects of other medications administered contemporaneously. For such oral administration, a pharmaceutically acceptable, non-toxic
10 composition is formed by the incorporation of any of the normally employed excipients, such as, for example, pharmaceutical grades of mannitol, lactose, starch, magnesium stearate, sodium saccharine, talcum, cellulose, glucose, gelatin, sucrose, magnesium carbonate, and the like. Such compositions take the form of solutions, suspensions, tablets, pills, capsules, powders, sustained release formulations and the like. Such
15 compositions may contain between .01 wt/wt% and 99.99 wt/wt% of the compound of Formula I, but preferably such compositions will contain between 25 wt/wt% and about 80 wt/wt%.

20 Preferably the compositions will take the form of a capsule, pill or tablet and thus the composition will contain, along with the active ingredient, a diluent such as lactose, sucrose, dicalcium phosphate, and the like; a disintegrant such as starch or derivatives thereof; a lubricant such as magnesium stearate and the like; and a binder such as a starch, polyvinylpyrrolidone, gum acacia, gelatin, cellulose and derivatives
25 thereof, and the like. For oral administration to infants, a liquid formulation (such as a syrup or suspension) is preferred.

AEROSOL ADMINISTRATION

30 Aerosol administration is an effective means for delivering a therapeutic agent directly to the respiratory tract. Some of the advantages of this method are: 1) it circumvents the effects of enzymatic degradation, poor absorption from the gastrointestinal tract, or loss of the therapeutic agent to the hepatic first-pass effect; 2) it administers therapeutic agents which would otherwise fail to reach
35 their target sites in the respiratory tract due to their molecular size, charge or affinity to extra-pulmonary sites; 3) it provides for fast absorption into the body via the alveoli of the lungs; and 4) it avoids exposing other organ systems to the therapeutic agent, which is important where exposure might cause undesirable side effects. For these reasons, aerosol administration is particularly advantageous for treatment of
40 asthma, local infections of the lung, and other diseases or disease conditions of the lung and respiratory tract.

There are three types of pharmaceutical inhalation devices, nebulizers inhalers, metered-dose inhalers (MDI) and dry powder inhalers
45 (DPI). Nebulizer devices produce a stream of high velocity air that causes

the therapeutic agent (which has been formulated in a liquid form) to spray as a mist which is carried into the patient's respiratory tract. MDIs typically have the formulation packaged with a compressed gas. Upon actuation, the device discharges a measured amount of therapeutic agent by compressed gas, thus affording a reliable method of administering a set amount of agent.

DPIs administer therapeutic agents in the form of a free flowing powder that can be dispersed in the patient's inspiratory air-stream during breathing by the device. In order to achieve a free flowing powder, the therapeutic agent is formulated with an excipient, such as lactose. A measured amount of the therapeutic agent is stored in a capsule form and is dispensed with each actuation. Examples of DPIs being used are Spinhaler[®] (for the administration of disodium cromoglycate), Rotahaler[®] (for albuterol) and Turbuhaler[®] (for terbutaline sulfate). All of the above methods can be used for administering the present invention, particularly for the treatment of asthma and other similar or related respiratory tract disorders.

LIPOSOMAL FORMULATIONS

Pharmaceutical formulations based on liposomes have recently reached human clinical trials. Their benefits are believed related to favorable changes in tissue distribution and pharmacokinetic parameters that result from liposome entrapment of drugs, and may be applied to the compounds of the present invention by those skilled in the art.

The formulations can be designed to either target drug to disease sites [see: Lopez-Berestein et al., *J. Infect. Dis.*, 151: 704-710 (1985); Gotfredsen et al., *Biochemical Pharmacology*, 32: 3389-3396 (1983)]; or to the reticuloendothelial system [see Eppstein et al., *Int. J. Immunotherapy*, 2: 115-126 (1986)], to increase duration of drug action [see: Gabizon et al., *Cancer Res.*, 42: 4734 (1982); Eppstein et al., *Delivery Systems for Peptide Drugs*, Eds. S.S. Davis, L. Illum and E. Tomlinson, Plenum Pub. Corp., New York, pp. 277-283; C.A. Hunt, *Biochemica et Biophysica Acta.*, 719: 450-463 (1982); and Senior et al., *Biochemica et Biophysica Acta.*, 839: 1-8 (1985)], or to divert a drug away from organs that are particularly sensitive to its toxic effects [see: Weinstein et al., *Pharmac. Ther.*, 24: 207-233 (1983); Olson et al., *Eur. J. Cancer Clin. Oncol.*, 18: 167-176 (1982); and Gabizon et al., *supra.*].

Controlled release liposomal liquid pharmaceutical formulations for injection or oral administration are described in U.S. Patent No. 4,016,100. Liposomal applications for oral drug delivery of a lyophilized liposome/peptide drug mixture filled into intestine capsules have also been suggested, see U.S. Patent No. 4,348,384.

2159603

-27-

SUPPOSITORIES

For systemic administration via suppository, traditional binders and carriers include, for example, polyalkaline glycol or triglycerides [e.g., PEG 1000 (96%) and PEG 4000 (4%)]. Such suppositories may be formed from mixtures containing active ingredients in the range of from about 0.5 wt/wt% to about 10 wt/wt%; preferably from about 1 wt/wt% to about 2 wt/wt%.

LIQUIDS

Liquid pharmaceutically administrable compositions can, for example, be prepared by dissolving, dispersing, etc. an active compound (about 0.5% to about 20%), as described above, and optional pharmaceutical adjuvants in a carrier, such as, for example, water, saline, aqueous dextrose, glycerol, ethanol and the like, to thereby form a solution or suspension.

Actual methods of preparing such dosage forms are known, or will be apparent, to those skilled in this art; for example, see *Remington's Pharmaceutical Sciences*, Mack Publishing Company, Easton, Pennsylvania, 16th Ed., 1980. The composition to be administered will, in any event, contain a quantity of the active compound(s) in a pharmaceutically effective amount for relief of the particular condition being treated in accordance with the teachings of this invention.

EXAMPLES

The following examples are given to enable those skilled in the art to more clearly understand and to practice the present invention. They should not be considered as limiting the scope of the invention, but merely as being illustrative and representative thereof.

EXAMPLE 1**PREPARATION OF 4-(4-AMINO BENZYL) PYRIDINE****1A. Formula 2, Where R¹ is 4-Pyridylmethyl**

4-(4-Nitrobenzyl)pyridine (214.22 mg) was combined with absolute ethanol (10 mL) and SnCl₂·2H₂O (225.63 mg). The reaction mixture was heated to 70°C under nitrogen for 2 hours. The progress of the reaction was monitored by thin-layer chromatography (e.g., an aliquot of the mixture was collected, neutralized with saturated NaHCO₃ to pH 7-8, extracted into ethyl acetate). When all of the starting material had been converted, the reaction mixture was allowed to cool to room temperature, neutralized with saturated NaHCO₃ to pH 7-8 and extracted with ethyl acetate. The organic layers were collected and dried over MgSO₄. The solvents were removed and the residue was triturated with ethyl ether. The desired product, i.e., 4-(4-aminobenzyl)pyridine, was filtered out of the solution as cream colored crystals and air dried, mp 159.1°C - 160.3°C; elemental analysis:

2159603

-28-

[calc(found)] C: 78.2 (78.12), H: 6.56 (6.45), and N: 15.20 (15.33).

1B. Compounds of Formula 2, Where R¹ Is Varied

Other desired compounds of Formula 2 can be prepared by following the procedures described in Example 1A, and using different starting compounds. For example: 4-isopropylnitrobenzene, 4-methylnitrobenzene, 4-benzylnitrobenzene, 4-ethylnitrobenzene, 4-(3-propenyl)nitrobenzene, 4-propylnitrobenzene, 4-butylnitrobenzene, 4-pentylnitrobenzene, 4-hexylnitrobenzene, 4-methoxynitrobenzene, 4-ethoxynitrobenzene, 4-(trifluoromethyl)nitrobenzene, 4-(3-pyridylmethyl)nitrobenzene, 4-(2-pyridylmethyl)nitrobenzene, 4-(cyclopentylmethyl)nitrobenzene, 4-(cyclopropylmethyl)nitrobenzene, 4-(thiomethyl)nitrobenzene, and 4-(methylsulfonylmethyl)nitrobenzene can be converted to the corresponding (substituted) anilines.

EXAMPLE 2

PREPARATION OF 4-(4-AMINO-3-BROMOBENZYL) PYRIDINE

2A. Formula 3, Where R¹ is 4-Pyridylmethyl

A solution of N-bromosuccinimide (1.4 gm) in 10 mL dimethylformamide was added in a dropwise manner to a solution of 4-(4-aminobenzyl)pyridine (1.5 gm) in 10 mL of dimethylformamide. The reaction flask was wrapped in aluminum foil to prevent exposure of the reagents to light. The reaction mixture was stirred at room temperature for 3 hours. The progress of the reaction was monitored by thin-layer chromatography. When the reaction was completed, the reaction mixture was combined with 100 mL of H₂O with stirring. A reddish brown precipitate was formed, filtered out of solution, washed with H₂O, and air dried. The solid was dissolved in ethyl acetate, back washed with saturated NaCl, dried over MgSO₄ and triturated with ethyl ether. The solid was filtered from the solution and air dried yielding 1.6 gm of 4-(4-amino-3-bromobenzyl)pyridine as reddish/tan crystals. mp 102.7°C-103.9°C;

2B. Other Prepared Compounds of Formula 3, Where R¹ Is Varied

Other compounds of Formula 3 were also prepared following the procedures described in Example 2A, and substituting 4-(4-aminobenzyl)pyridine with different starting compounds. For example, following is a list of starting compounds and the corresponding desired compounds that were obtained by following the above-referenced procedure:

4-isopropylaniline was converted to 2-bromo-4-isopropylaniline, 4-methylaniline was converted to 2-bromo-4-methylaniline, 4-benzylaniline was converted to 4-benzyl-2-bromoaniline, and 4-(4-pyridylmethyl)aniline was converted to 2-bromo-4-(4-pyridylmethyl)aniline.

2159603

-29-

2C. Compounds of Formula 3, Where R¹ Is Varied

In addition, other desired compounds of Formula 3 can be prepared by following the procedures described in Example 2A, and using different starting compounds.

For example, 4-ethylaniline, 4-(3-propenyl)aniline, 4-propylaniline, 4-butaniline, 4-pentylaniline, 4-hexylaniline, 4-trifluoromethylaniline, 4-(3-pyridylmethyl)aniline, 4-(2-pyridylmethyl)aniline, 4-(cyclopentylmethyl)aniline, 4-(cyclopropylmethyl)aniline, 4-(methylthiomethyl)aniline, and 4-(methylsulfonylmethyl)aniline can be converted to the corresponding 2-bromo-4-(substituted)-anilines.

EXAMPLE 3

PREPARATION OF

3-CHLOROBENZENE BORONIC ACID

3A. Formula 3B Where R² is 3-chlorophenyl

A solution of trimethylborate in 200 mL of ethyl acetate was cooled to -65°C. 3-Chlorobenzene magnesium chloride (0.8 M, 60 mL), i.e., a Grignard reagent, was added to the solution in a dropwise manner over 20 minutes. The mixture was kept in the temperature range of -60°C to -70°C and stirred. After 30 minutes, the mixture was allowed to warm to 0°C and stirred for 1 hour. The mixture was quenched with H₂O (25 mL) and stirred at room temperature for 1 hour. The solvent was removed and the remaining mass was extracted with ethyl ether (3 x 100 mL). The organic layers were combined and washed with H₂O (2 x 50 mL), dilute HCl (2 x 100 mL), H₂O (2 x 50 mL) and brine (1 x 50 mL). The organic layer was dried over MgSO₄, concentrated and allowed to stand. 100 mL of hexanes was added and the solution was stirred for 1 hour. The solution was filtered and allowed to air dry yielding 4.6 g of 3-chlorobenzene boronic acid as a white solid.

3B. Compounds of Formula 3B where R² is optionally substituted

Other desired compounds of Formula 3B can be prepared by following the procedures described in Example 3A, and using different starting compounds. For example, 3-chloro-4-fluorobenzene magnesium chloride, 4-chlorobenzene magnesium chloride, benzene magnesium bromide, 3,4-dichlorobenzene magnesium bromide, 3-bromobenzene magnesium bromide, and 3-(trifluoromethyl)benzene magnesium bromide can be converted to the corresponding (substituted) benzene boronic acids.

EXAMPLE 4

PREPARATION OF 4-[4-AMINO-3-(3-NITROPHENYL)- BENZYL] PYRIDINE

4A. Formula 4, Where R¹ is 4-Pyridylmethyl, R² is 3-Nitrophenyl.

-30-

4-(4-Amino-3-bromobenzyl)pyridine (1.0 gm), 3-nitrobenzene boronic acid (0.63 gm), palladium tetrakis triphenylphosphine (0.47 gm), methanol (6.5 mL), 2.0 M Na₂CO₃ (1.9 mL) and benzene (32 mL) were combined in a reaction flask that was wrapped in aluminum foil (to prevent exposure of the reagents to light). The reaction mixture was heated under reflux for 6 hours. The progress of the reaction was monitored by thin-layer chromatography (9:1 hexane:ethyl acetate). When the starting material was converted, the reaction mixture was allowed to cool and the solvents were removed. Ethyl acetate was added to the residue, the resultant solution was filtered through a pad of Na₂SO₄, and concentrated. The product was isolated by preparative thin-layer chromatography (9:1 hexane:ethyl acetate) yielding 983 mg of 4-[4-amino-3-(3-nitrophenyl)benzyl]pyridine as an orange oil.

Characteristic analytical data: ms m/e 305(M⁺); ¹H NMR (CDCl₃) δ 3.74 (bs, 2H), 3.92 (s, 2H), 6.77 (d, 1H, J=8.1 Hz), 6.95 (d, 1H, J=2.1 Hz), 7.03 (dd, 1H, J=2.1 Hz, J=8.1 Hz), 7.14 (d, 1H, J=5.7 Hz), 7.62 (dd, 1H, J=8.2 Hz, J=7.7 Hz), 7.82 (ddd, 1H, J=7.7 Hz, J=1.9 Hz, J=2.5 Hz), 8.21 (ddd, 1H, J=8.2 Hz, J=2.5 Hz, J=1.9 Hz), 8.34 (dd, 1H, J=1.9 Hz, J=1.9 Hz), and 8.5 (dd, 1H, J=5.7 Hz).

4B. Other Compounds of Formula 4, Where R¹ and R² Are Varied.

Other compounds of Formula 4 were also prepared following the procedures described in Example 4A, and substituting for 4-(4-amino-3-bromobenzyl)pyridine and 3-nitrobenzene boronic acid with different starting compounds. For example, following is a list of starting compounds and the corresponding desired compounds that were obtained by following the above-referenced procedure:

2-bromo-4-isopropylaniline and benzene boronic acid were combined to form 2-phenyl-4-isopropylaniline,

2-bromo-4-isopropylaniline and 3-nitrobenzene boronic acid were combined to form 2-(3-nitrophenyl)-4-isopropylaniline,

4-benzyl-2-bromo-aniline and 3-nitrobenzene boronic acid were combined to form 4-benzyl-2-(3-nitrophenyl)-aniline,

2-bromo-4-methylaniline and 3-chloro-4-fluorobenzene boronic acid were combined to form 2-(3-chloro-4-fluorophenyl)-4-methylaniline,

2-bromo-4-isopropylaniline and 3-chloro-4-fluorobenzene boronic acid were combined to form 2-(3-chloro-4-fluorophenyl)-4-isopropylaniline,

4-benzyl-2-bromo-aniline and 3-chloro-4-fluorobenzene boronic acid were combined to form 4-benzyl-2-(3-chloro-4-fluorophenyl)-aniline,

2-bromo-4-(4-pyridylmethyl)aniline and 3-chloro-4-fluorobenzene boronic acid were combined to form 2-(3-chloro-4-fluorophenyl)-

4 - (4-pyridylmethyl) aniline,
2-bromo-4-methylaniline and 4-chlorobenzene boronic acid were
combined to form 2-(4-chlorophenyl)-4-methylaniline,
2-bromo-4-isopropylaniline and 4-chlorobenzene boronic acid were
combined to form 2-(4-chlorophenyl)-4-isopropyl aniline, and
2-bromo-4-benzylaniline and 4-chlorobenzene boronic acid were
combined to form 2-(4-chlorophenyl)-4-benzyl- aniline.

4C. Compounds of Formula 4, Where R¹ and R² Are Varied

In addition, other desired compounds of Formula 4 can be prepared by
following the procedures described in Example 4A, and using different
starting compounds. For example,

2-bromo-4-ethylaniline and 3-(trifluoromethyl)benzene boronic acid
can be combined to form 2-(3-trifluoromethylphenyl)-4-
ethylaniline,

2-bromo-4-isopropylaniline and 3,4-dichlorobenzene boronic acid can
be combined to form 2-(3,4-dichlorophenyl)-4-isopropylaniline,
2-bromo-4-(3-propenyl)aniline and 3-nitrobenzene boronic acid can be
combined to form 2-(3-nitrophenyl)-3-propenylaniline,

2-bromo-4-propylaniline and 3-nitrobenzene boronic acid can be
combined to form 2-(3-nitrophenyl)-4-propylaniline,

2-bromo-4-(n-butyl)aniline and 3-nitrobenzene boronic acid can be
combined to form 2-(3-nitrophenyl)-4-(n-butyl)aniline,

2-bromo-4-(n-hexyl)aniline and benzene boronic acid can be combined
to form 2-phenyl-4-(n-hexyl)aniline,

2-bromo-4-pentylaniline and 3-nitrobenzene boronic acid can be
combined to form 2-(3-nitrophenyl)-4-pentylaniline,

2-bromo-4-benzylaniline and 3,4-dichlorobenzene boronic acid can be
combined to form 2-(3,4-dichlorophenyl)-4-benzylaniline,

2-bromo-4-cyclopentylmethylaniline and 3-chlorobenzene boronic acid
can be combined to form 2-(3-chlorophenyl)-4-
cyclopentylmethylaniline,

2-bromo-4-cyclopropylmethylaniline and 3-nitrobenzene boronic acid
can be combined to form 2-bromo-4-cyclopropyl- methylaniline,

2-bromo-4-(methylthiomethyl)aniline and 3-chlorobenzene boronic acid
can be combined to form 2-(3-chlorophenyl)-4-
(methylthiomethyl)aniline,

2-bromo-4-(methylsulfonylmethyl)aniline and benzene boronic acid can
be combined to form 2-phenyl-4-(methylsulfonyl- methyl)aniline,

2-bromo-4-(cyclopentylmethyl)aniline and 2,3-dichlorobenzene boronic
acid can be combined to form 2-(2,3-dichlorophenyl)-4-
(cyclopentylmethyl)aniline, and

2-bromo-4-(cyclopentylmethyl)aniline and 3-nitrobenzene boronic acid
can be combined to form 2-(3-nitrophenyl)-4-
(cyclopentylmethyl)aniline.

EXAMPLE 5

PREPARATION OF 6-(4-PYRIDYLMETHYL)-8-(3-NITROPHENYL)QUINOLINE

5A. Formula I, Where R¹ is 4-Pyridylmethyl, R² is 3-Nitrophenyl.

5 4-[4-Amino-3-(3-nitrophenyl)benzyl]pyridine (600 mg) was combined with glycerol (489 mg) and arsenic pentoxide (325 mg) under nitrogen. The reaction mixture was heated to 100°C for 30 minutes. Concentrated sulfuric acid (406 mg) was added in a dropwise manner and the reaction mixture was further heated to 150°C for 2 hours. The reaction was monitored by TLC (9:1, hexane:ethyl acetate). When TLC indicated that greater than 90% of the starting material had been converted, the reaction mixture was removed from the heat, ice (approximately 1 gm) was added, and NH₄OH was added to basify the mixture. A precipitate was filtered out of the mixture, washed with H₂O and air dried.

15 The resulting solid was suspended in hot ethyl acetate and filtered. The filtrate was concentrated and chromatographed by preparative thin-layer chromatography (4:1, hexane:ethyl acetate), the band with the higher R_f value was isolated yielding 181 mg of 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline as a viscous yellow oil. The product was recrystallized from diethyl ether as a light yellow solid.

20 Characteristic analytical data: mp 131°C-143°C; elemental analysis, calc(found) C: 73.89 (73.90), H: 4.43 (4.50), and N: 12.31 (12.30); ¹H NMR CDCl₃, δ 4.21 (s, 2H), 7.21 (d, 2H, J=5.9 Hz), 7.48 (dd, 1H, J=8.3 Hz, J=4.2 Hz), 7.6 (d, 1H, J=2 Hz), 7.66 (dd, 1H, J=8 Hz, J=7.7 Hz), 7.7 (d, 1H, J=2Hz), 8.03 (ddd, 1H, J=7.7 Hz, J=1.4 Hz, J=1.2 Hz), 8.2 (dd, 1H, J=8.3 Hz, J=1.7 Hz, J=1.2 Hz), 8.28 (ddd, 1H J=8 Hz, J=1.44 Hz, J=1.2 Hz), 8.55(m, 3H), 8.93 (dd, 1H, J=4.2 Hz, J=1.7 Hz).

5B. Other Compounds of Formula I, Where R¹ and R² Are Varied.

30 Other compounds of Formula I were also prepared following the procedures described in Example 5A, and substituting 4-[4-amino-3-(3-nitrophenyl)benzyl]pyridine with different starting compounds. For example, following is a list of starting compounds and the corresponding desired compounds that were obtained by following the above-referenced procedure:

2-phenyl-4-isopropylaniline was converted to 6-isopropyl-8-phenylquinoline as an oil,

2-(3-nitrophenyl)-4-isopropylaniline was converted to 6-isopropyl-8-(3-nitrophenyl)quinoline as an oil,

40 4-benzyl-2-(3-nitrophenyl)aniline was converted to 6-benzyl-8-(3-nitrophenyl)quinoline, mp 101°C-103°C,

2-(3-chloro-4-fluorophenyl)-4-methylaniline was converted to 6-methyl-8-(3-chloro-4-fluorophenyl)quinoline, mp 96°C-114°C,

2-(3-chloro-4-fluoro)-4-isopropylaniline was converted to

2159603

6-isopropyl-8-(3-chloro-4-fluorophenyl)quinoline as an oil,
4-benzyl-2-(3-chloro-4-fluorophenyl)aniline was converted to 6-
benzyl-8-(3-chloro-4-fluorophenyl)quinoline as an oil,
2-(3-chloro-4-fluorophenyl)-4-(4-pyridylmethyl)aniline was converted
5 to 6-(4-pyridylmethyl)-8-(3-chloro-4-fluorophenyl)quinoline as
an oil,
2-(4-chlorophenyl)-4-methylaniline was converted to 6-methyl-8-(4-
chlorophenyl)quinoline, mp 96°C-98°C,
2-(4-chlorophenyl)-4-isopropylaniline was converted to 6-isopropyl-8-
10 (4-chlorophenyl)quinoline as an oil, and
4-benzyl-2-(4-chlorophenyl)aniline was converted to 6-benzyl-8-(4-
chlorophenyl)quinoline as an oil.

5C. Formula I, Where R¹ and R² Are Varied

15 In addition, other desired compounds of Formula I can be prepared by
following the procedures described in Example 5A, and using different
starting compounds. For example,

2-(3-trifluoromethylphenyl)-4-ethylaniline can be converted to
6-ethyl-8-(3-trifluoromethylphenyl)quinoline,

20 2-(3,4-dichlorophenyl)-4-isopropylaniline can be converted to
6-isopropyl-8-(3,4-dichlorophenyl)quinoline,

2-(3-nitrophenyl)-4-(3-propenyl)aniline can be converted to
6-(3-propenyl)-8-(3-nitrophenyl)quinoline,

25 2-(3-nitrophenyl)-4-propylaniline can be converted to
6-propyl-8-(3-nitrophenyl)quinoline,

2-(3-nitrophenyl)-4-butyylaniline can be converted to
6-butyl-8-(3-nitrophenyl)quinoline,

2-(phenyl)-4-hexylaniline can be converted to
6-hexyl-8-(phenyl)quinoline,

30 2-(3-nitrophenyl)-4-pentyylaniline can be converted to
6-pentyl-8-(3-nitrophenyl)quinoline,

2-(3,4-dichlorophenyl)-4-benzylaniline can be converted to
6-benzyl-8-(3,4-dichlorophenyl)quinoline,

35 2-(3-methoxycarbonylphenyl)-4-(3-pyridylmethyl)aniline can be
converted to 6-(3-pyridylmethyl)-8-(3-methoxycarbonylphenyl)-
quinoline,

2-(3-methoxycarbonylphenyl)-4-(2-pyridylmethyl)aniline can be
converted to 6-(2-pyridylmethyl)-8-(3-methoxycarbonylphenyl)-
quinoline,

40 2-(3-chlorophenyl)-6-cyclopentylmethylaniline can be converted to 6-
cyclopentylmethyl-8-(3-chlorophenyl)quinoline,

2-(3-nitrophenyl)-4-cyclopropylmethylaniline can be converted to 6-
cyclopropylmethyl-8-(3-nitrophenyl)quinoline,

45 2-(3-chlorophenyl)-4-(methylthiomethyl)aniline can be converted to 6-
methylthiomethyl-8-(3-chlorophenyl)quinoline,

2-phenyl-4-(methylsulfonylmethyl)aniline can be converted to 6-methylsulfonylmethyl-8-(phenyl)quinoline,
2-(3,4-dichlorophenyl)-4-(cyclopentylmethyl)aniline can be converted to 6-cyclopentylmethyl-8-(3,4-dichlorophenyl)quinoline, and
5 2-(3-nitrophenyl)-4-(cyclohexylmethyl)aniline can be converted to 6-cyclohexylmethyl-8-(3-nitrophenyl)quinoline.

EXAMPLE 6

PREPARATION OF 6-ISOPROPYL-8-BROMOQUINOLINE

10 6A. Formula 5 Where R¹ Is Isopropyl

2-Bromo-4-isopropylaniline (3.0 gm) [obtained from Aldrich Chemical Co.], glycerol (2.8 Ml) and arsenic pentoxide (3.22 g) were combined and heated to 100°C. H₂SO₄ (concentrated, 1.9 Ml) was added to the reaction mixture in a dropwise manner. The mixture was then heated to 150°C for 2.5
15 hours. The resulting black oil was added in a dropwise manner to a stirring mixture of saturated NaHCO₃ (300 Ml) and ethyl acetate (100 Ml). After completion of the addition, the reaction mixture was stirred for 30 minutes. The reaction mixture was then extracted with ethyl acetate (2 x 200 Ml). The organic layers were washed with brine, dried over MgSO₄,
20 filtered and concentrated. The resulting material was further purified and isolated by chromatography on silica gel (30:70 ethyl acetate/hexanes) which yielded 2.5 g of 6-isopropyl-8-bromoquinoline as a brown oil.

Characteristic analytical data: elemental analysis calc.(found): C 57.62 (57.65), H 4.84 (4.78), and N 5.60 (5.57); ¹H NMR (CDCl₃) δ 1.34 (d, 6H, J=6.9 Hz), 3.05 (m, 1H, J=6.9 Hz), 7.42 ((dd, 1H, J=4.2 Hz, J=8.3 Hz), 7.57 (d, 1H, J=1.8 Hz), 7.97 (d, 1H, J=1.8 Hz), 8.1 (dd, 1H, J=8.3 Hz, J=1.7 Hz), and 8.9 (dd, 1H, J=4.2 Hz, J=1.7 Hz).

EXAMPLE 7

30 PREPARATION OF 6-ISOPROPYL-

8-(3-NITROPHENYL)QUINOLINE HYDROCHLORIDE

7A. Formula I Where R¹ Is Isopropyl and R² Is 3-Nitrophenyl.

6-Isopropyl-8-bromoquinoline (1.15 g) was dissolved in 46 Ml of ethanol/benzene (1:1). 3-Nitrobenzene boronic acid (1.4 g), Na₂CO₃
35 (2M, 9.2 Ml) and tetrakis(triphenylphosphine)palladium (0.23 g) were added successively. The reaction mixture was refluxed for 6 hours and then cooled and concentrated. The resulting residue was partitioned between 75 mL H₂O and 100 mL of ethyl acetate, and extracted with ethyl acetate (2 x 100 mL). The extracts were then dried over MgSO₄, filtered, concentrated
40 and chromatographed on silica gel (20:80 ethyl acetate:hexane) yielding 1.2 g of 6-isopropyl-8-(3-nitrophenyl)-quinoline as a slightly impure yellow oil.

The desired product was obtained in its pure form by recrystallization of its hydrochloride salt. The oil was dissolved in 25

2159603

mL of 10% methanol:methylene chloride, to which a solution of 1M HCl/Et₂O (100 mL) was added. The solution was stirred for 10 minutes and then concentrated. The resulting white solid was recrystallized from ethyl acetate:ethanol yielding 0.74 g of 6-isopropyl-8-(3-nitrophenyl)quinoline as pale yellow crystals.

Characteristic analytical data: elem. anal. calc. (found):
C 65.75 (65.92), H 5.21 (5.21), and N 8.52 (8.67); and ¹H NMR (DMSO) δ 1.37 (d, 6H, J=6.9 Hz), 3.2 (m, 1H, J=6.9 Hz), 7.81 (m, 2H), 7.92 (d, 1H, J=1.9 Hz), 8.09 (d, 1H, J=1.9 Hz), 8.11 (m, 1H), 8.43 (m, 1H), 8.53 (m, 1H), 8.7 (dd, 1H, J=1.5 Hz, J=8.3 Hz), 8.9 (dd, 1H, J=4.7 Hz, J=8.3 Hz).

EXAMPLE 8 PREPARATION OF

6-METHYL-8-BROMOQUINOLINE

8A. Formula 5 Where R¹ is Methyl and X is Bromo

A slurry of 2-bromo-4-methylaniline (5 g), glycerol (6.7 g), and arsenic pentoxide (3.9 g) was formed and heated to 100°C for 30 minutes. Concentrated H₂SO₄ (4.9 g) was added dropwise and the mixture was heated to 150°C for two hours. The progress of the reaction was monitored by thin-layer chromatography (9:1 hexane:ethyl acetate). Upon completion, the reaction mixture was worked up by adding water, basifying with saturated NaHCO₃, extracting with ethyl acetate, and drying the organic layer over MgSO₄. The desired product was isolated and purified by column chromatography (9:1 hexane:ethyl acetate), yielding 6-methyl-8-bromoquinoline (1.8 g) as a yellow liquid.

Characteristic analytical data: ¹H NMR (CDCl₃) δ 2.5 (s, 3H), 7.4 (dd, 1H, J=8.3 Hz, J=4.3 Hz), 7.52 (bs, 1H), 7.9 (d, 1H, J=1.8 Hz), 8.07 (dd, 1H, J=8.3 Hz, J=1.7 Hz), 8.88 (dd, 1H, J=4.3 Hz, J=1.7 Hz).

8B. Formula 5 Where R¹ Is Varied

Following the procedures described in Example 8A the following desired compounds of Formula 5 can be obtained from the indicated starting compounds. For example,

2-bromo-4-isopropylaniline and glycerol can be combined to form 6-isopropyl-8-bromoquinoline,

2-bromo-4-methylaniline and glycerol can be combined to form 6-methyl-8-bromoquinoline,

2-bromo-4-benzylaniline and glycerol can be combined to form 6-benzyl-8-bromoquinoline,

2-bromo-4-(4-pyridylmethyl)aniline and glycerol can be combined to form 6-(4-pyridylmethyl)-8-bromoquinoline,

2-bromo-4-ethylaniline and glycerol can be combined to form 6-ethyl-8-bromoquinoline,

-36-

2-bromo-4-(3-propenyl)aniline and glycerol can be combined to form 6-(3-propenyl)-8-bromoquinoline,

2-bromo-4-propylaniline and glycerol can be combined to form 6-propyl-8-bromoquinoline,

2-bromo-4-(n-butyl)aniline and glycerol can be combined to form 6-(n-butyl)-8-bromoquinoline,

2-bromo-4-pentylaniline and glycerol can be combined to form 6-pentyl-8-bromoquinoline,

2-bromo-4-hexylaniline and glycerol can be combined to form 6-hexyl-8-bromoquinoline,

2-bromo-4-(3-pyridylmethyl)aniline and glycerol can be combined to form 6-(3-pyridylmethyl)-8-bromoquinoline,

2-bromo-4-(2-pyridylmethyl)aniline and glycerol can be combined to form 6-(2-pyridylmethyl)-8-bromoquinoline,

2-bromo-4-(cyclopentylmethyl)aniline and glycerol can be combined to form 6-(cyclopentylmethyl)-8-bromoquinoline,

2-bromo-4-(cyclopropylmethyl)aniline and glycerol can be combined to form 6-(cyclopropylmethyl)-8-bromoquinoline,

2-bromo-4-(methylthiomethyl)aniline and glycerol can be combined to form 6-(methylthiomethyl)-8-bromoquinoline, and

2-bromo-4-(methylsulfonylmethyl)aniline and glycerol can be combined to form 6-(methylsulfonylmethyl)-8-bromoquinoline.

EXAMPLE 9

PREPARATION OF

6-METHYL-8-(3-NITROPHENYL)QUINOLINE

9A. Formula I, Where R¹ is Methyl and R² is 3-Nitrophenyl.

To a mixture of 6-methyl-8-bromoquinoline (1.0 g), 3-nitrobenzene boronic acid (0.63 g), purchased from Lancaster Chemicals, 2M NaCO₃ (1.9 mL), methanol (6.5 mL) and benzene 32 mL) was added palladium tetrakis triphenylphosphine (0.47 g). The mixture was heated under reflux for 6 hours. The progress of the reaction was monitored by thin-layer chromatography. Upon completion, the reaction mixture was cooled and the solvents removed. Ethyl acetate was added to the residue and the solution was filtered through a pad of Na₂SO₄. The solution was concentrated and the desired product was purified and isolated by preparative thin-layer chromatography yielding 6-methyl-8-(3-nitrophenyl)quinoline (983 mg) as a yellow oil. Elemental analysis [calc.(found)] C: 72.72 (72.63), H: 4.58 (4.32), and N: 10.60 (10.72).

9B. Formula I, Where R¹ and R² Are Varied

The compounds of Formula I that were prepared following the procedures described in Examples 1-5 (i.e., following Reaction Scheme A) can also be prepared by following the procedures described in Examples 6,

7, 8 and 9 (i.e., following Reaction Scheme B).

For example,

6-isopropyl-8-bromoquinoline combined with benzene boronic acid can be converted to 6-isopropyl-8-phenylquinoline,

6-isopropyl-8-bromoquinoline combined with 3-nitrobenzene boronic acid can be converted to 6-isopropyl-8-(3-nitrophenyl)-quinoline,

6-benzyl-8-bromoquinoline combined with 3-nitrobenzene boronic acid can be converted to 6-benzyl-8-(3-nitrophenyl)quinoline,

6-methyl-8-bromoquinoline combined with 3-chloro-4-fluorobenzene boronic acid can be converted to 6-methyl-8-(3-chloro-4-fluorophenyl)quinoline,

6-isopropyl-8-bromoquinoline combined with 3-chloro-4-fluoro- benzene boronic acid can be converted to 6-isopropyl-8-(3-chloro-4-fluorophenyl)quinoline,

6-benzyl-8-bromoquinoline combined with 3-chloro-4-fluorobenzene boronic acid can be converted to 6-benzyl-8-(3-chloro-4-fluorophenyl)quinoline,

6-(4-pyridylmethyl)-8-bromoquinoline combined with 3-chloro-4-fluorobenzene boronic acid can be converted to 6-(4-pyridylmethyl)-8-(3-chloro-4-fluorophenyl)quinoline,

6-methyl-8-bromoquinoline combined with 4-chlorobenzene boronic acid can be converted to 6-methyl-8-(4-chlorophenyl)- quinoline,

6-isopropyl-8-bromoquinoline combined with 4-chlorobenzene boronic acid can be converted to 6-isopropyl-8-(4-chlorophenyl)quinoline, and

6-benzyl-8-bromoquinoline combined with 4-chlorobenzene boronic acid can be converted to 6-benzyl-8-(4-chlorophenyl)- quinoline.

9C. Formula I, Where R¹ and R² Are Varied

In addition, other desired compounds of Formula I can be prepared by following the procedures described in Example 9A, and using different starting compounds. For example,

6-ethyl-8-bromoquinoline and 3,4 dichlorobenzene boronic acid can be combined to form 6-ethyl-8-(3,4-dichlorophenyl)quinoline,

6-(3-propenyl)-8-bromoquinoline and 3-(trifluoromethyl)benzene boronic acid can be combined to form 6-(3-propenyl)-8-(3-trifluoromethylphenyl)quinoline,

6-propyl-8-bromoquinoline and 3-nitrobenzene boronic acid can be combined to form 6-propyl-8-(3-nitrophenyl)quinoline,

6-(n-butyl)-8-bromoquinoline and 3-chlorobenzene boronic acid can be combined to form 6-(n-butyl)-8-(3-chlorophenyl)quinoline,

6-pentyl-8-bromoquinoline and 3,4-dichlorobenzene boronic acid can be combined to form 6-pentyl-8-(3,4-dichlorophenyl)quinoline,

6-hexyl-8-bromoquinoline and 3-nitrobenzene boronic acid can be

2159603

-38-

combined to form 6-hexyl-8-(3-nitrophenyl)quinoline,
6-(3-pyridylmethyl)-8-bromoquinoline and 3-nitrobenzene boronic acid
can be combined to form 6-(3-pyridylmethyl)-8-

(3-nitrophenyl)quinoline,

6-(2-pyridylmethyl)-8-bromoquinoline and 3-chlorobenzene boronic acid
can be combined to form 6-(2-pyridylmethyl)-
8-(3-chlorophenyl)quinoline,

6-(cyclopentylmethyl)-8-bromoquinoline and 3-chloro-4-fluorobenzene
boronic acid can be combined to form 6-(cyclopentylmethyl)-8-
(3-chloro-4-fluorophenyl)quinoline,

6-(cyclopropylmethyl)-8-bromoquinoline and benzene boronic acid can
be combined to form 6-(cyclopropylmethyl)-8-phenyl- quinoline,
6-(methylthiomethyl)-8-bromoquinoline and benzene boronic acid can be
combined to form 6-(methylthiomethyl)-8-phenylquinoline, and

6-(methylsulfonylmethyl)-8-bromoquinoline and 3-nitrobenzene boronic
acid can be combined to form 6-(methylsulfonyl- methyl)-8-(3-
nitrophenyl)quinoline.

EXAMPLE 10

PREPARATION OF

8-(3-CHLOROPHENYL)-6-QUINOLINECARBOXALDEHYDE

10A. Formula I Where R¹ is Bromomethyl

6-Methyl-8-(3-chlorophenyl)quinoline (prepared following the
procedures described in Example 9, Reaction Scheme B) (1.64 g) was combined
with 30 mL of carbon tetrachloride and heated to reflux.

N-Bromosuccinamide (1.34 g) and 2,2'-azobis(2-methylpropionitrile) (0.025
g) was added and the reaction mixture was exposed to light from a 250 watt
light bulb for 1 hour. The reaction mixture was then stirred for an
additional 2 hours. The progress of the reaction was monitored by thin-
layer chromatography (9:1 hexane/ethyl acetate). Upon completion of the
reaction, the reaction mixture was cooled to 0°C and poured through a
2cm pad of Na₂SO₄ on 1cm pad on silica gel. The filtrate was concentrated
yielding 2.26 g of a yellow oil as a mixture of the monobrominated compound
as the major product as well as the dibrominated compound as the minor
product. The crude oil (1.84 g) was dissolved in 25 mL of chloroform and
added dropwise to a solution of tetra n-butylammonium dichromate (19.4 g)
in methylene chloride (30 mL) and refluxed for 4 hours. The reaction
mixture was then cooled to room temperature, filtered through silica gel,
eluted with ether and concentrated. The residue was chromatographed in
hexane:ethyl acetate (70:30) to obtain 8-(3-chlorophenyl)-6-
quinolinecarboxaldehyde
(0.93 g).

Characteristic analytical data: ¹H NMR (CDCl₃) δ 7.41 (m, 2H) 7.52
(dd, 1H, J=5.2 Hz, J=4.2 Hz), 7.6 (m, 1H), 7.71 (m, 1H), 8.19 (d, 1H, J=1.9

Hz), 8.38 (d, 1H, J=1.9 Hz), 8.4 (dd, 1H, J=5.2 Hz, J=1.8 Hz), 9.6 (dd, 1H, J=4.2 Hz, J=1.8 Hz), 10.22 (s, 1H); and elemental analysis for $C_{16}H_{10}ClNO$, calc(found) C, 71.78 (71.79); H, 3.77 (3.81); N, 5.23 (5.39).

5 10B. Formula I, Where R^1 Is Bromomethyl and R^2 Is Varied.

Following the procedures described in Example 10A the following desired compounds of Formula I where R^1 is bromomethyl can be obtained from the indicated starting compounds. For example,

6-methyl-8-(3-nitrophenyl)quinoline can be converted to

8-(3-nitrophenyl)-6-quinolinecarboxaldehyde,

6-methyl-8-phenylquinoline can be converted to

8-phenyl-6-quinolinecarboxaldehyde,

6-methyl-8-(3-chlorophenyl)quinoline can be converted to

8-(3-chlorophenyl)-6-quinolinecarboxaldehyde,

6-methyl-8-(3-trifluoromethylphenyl)quinoline can be converted to 8-

(3-trifluoromethylphenyl)-6-quinolinecarboxaldehyde,

6-methyl-8-(3-chlorophenyl)quinoline can be converted to

8-(3-chlorophenyl)-6-quinolinecarboxaldehyde,

6-methyl-8-(3-chloro-4-fluoro-phenyl)quinoline can be converted to 8-

(3-chloro-4-fluorophenyl)-6-quinolinecarboxaldehyde,

6-methyl-8-(3,4-dichlorophenyl)quinoline can be converted to

8-(3,4-dichlorophenyl)-6-quinolinecarboxaldehyde, and

6-methyl-8-(4-chlorophenyl)quinoline can be converted to

8-(4-chlorophenyl)-6-quinolinecarboxaldehyde.

EXAMPLE 11

PREPARATION OF

6-(1-HYDROXYETHYL)-8-(3-CHLOROPHENYL)QUINOLINE

11A. Formula I Where R^1 Is 1-hydroxyethyl

8-(3-Chlorophenyl)-6-quinolinecarboxaldehyde (0.8 g) was dissolved in 20 mL of tetrahydrofuran and cooled to $-78^{\circ}C$. Methylolithium (4.5 mL, 1.4M) in diethyl ether was added dropwise to the solution over 5 minutes. The solution was stirred for 20 minutes, poured into 50 mL of saturated ammonium chloride, stirred for 5 minutes and extracted with ethyl acetate (2 x 75 mL). The extracts were combined and dried over $MgSO_4$, and concentrated. The residue was chromatographed on silica gel (30:70 ethyl acetate:hexanes) to obtain 0.72 g of 6-(1-hydroxyethyl)-8-(3-chlorophenyl)-quinoline as a yellow oil.

Characteristic analytical data: 1H NMR ($CDCl_3$) δ 1.6 (d, 3H, J=6.5 Hz), 5.1 (q, 1H, J=6.5 Hz), 7.4 (m, 3H), 7.55 (m, 1H), 7.67 (m, 1H), 7.7 (d, 1H, J=1.9 Hz), 7.8 (d, 1H, J=1.9 Hz), 8.18 (dd, 1H, J=8.3 Hz, J=1.8 Hz), 8.9 (dd, 1H, J=4.2 Hz, J=1.8 Hz).

11B. Formula I, Where R¹ Is Formyl and R² Is Varied

Following the procedures described in Example 11A the following desired compounds of Formula I where R¹ is formyl can be obtained from the indicated starting compounds. For example,

5 8-(3-nitrophenyl)-6-quinolinecarboxaldehyde and methyllithium can be converted to 6-(1-hydroxyethyl)-8-(3-nitrophenyl)-quinoline, 8-phenyl-6-quinolinecarboxaldehyde and *n*-butyl magnesium chloride can be converted to 6-(1-hydroxypentyl)-8-phenylquinoline, 8-(3-chlorophenyl)-6-quinolinecarboxaldehyde and ethyllithium can be
10 converted to 6-(1-hydroxypropyl)-8-(3-chlorophenyl)-quinoline, 8-(3-trifluoromethylphenyl)-6-quinolinecarboxaldehyde and hexyl magnesium chloride can be converted to 6-(1-hydroxy-heptyl)-8-(3-trifluoromethylphenyl)quinoline, 8-(3-chlorophenyl)-6-quinolinecarboxaldehyde and methyl magnesium
15 chloride can be converted to 6-(1-hydroxyethyl)-8-(3-chlorophenyl)quinoline, 8-(3-chloro-4-fluorophenyl)-6-quinolinecarboxaldehyde and methyllithium can be converted to 6-(1-hydroxyethyl)-8-(3-chloro-4-fluorophenyl)quinoline, 8-(3,4-dichlorophenyl)-6-quinolinecarboxaldehyde and propyllithium
20 can be converted to 6-(1-hydroxybutyl)-8-(3,4-dichlorophenyl)quinoline, and 8-(4-chlorophenyl)-6-quinolinecarboxaldehyde and hexyllithium can be converted to 6-(1-hydroxyheptyl)-8-(4-chlorophenyl)-
25 quinoline.

EXAMPLE 12**PREPARATION OF****6-(4-PYRIDYL-N-OXIDE-METHYL)-8-(3-NITROPHENYL)QUINOLINE**

30 To a solution of 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline (100 mg) in methylene chloride (10 mL) under nitrogen at room temperature was added *m*-chloroperoxybenzoic acid (59 mg). The reaction mixture was stirred at room temperature for 3½ hours. The progress of the reaction was monitored by TLC. Upon completion of the reaction, the reaction mixture
35 was worked up by preparative thin-layer chromatography yielding 6-(4-pyridyl-N-oxide-methyl)-8-(3-nitrophenyl)quinoline (87 mg) as creme colored crystals.

Characteristic analytical data: ¹H (CDCl₃) δ 4.21 (s, 2H), 7.13 (d, 2H, J=5.2 Hz), 7.43 (dd, 1H, J=8.2 Hz, J=4.2 Hz), 7.5 (d, 1H, J=1.9 Hz),
40 7.6 (dd, 1H, J=8 Hz, J=8 Hz), 7.7 (d, 1H, J=1.9 Hz), 7.95 (ddd, 1H J=7.7 Hz, J=1.4 Hz, J=1.3 Hz), 8.13 (d, 2H, J=5.2 Hz), 8.18 (dd, 1H, J=8.2 Hz, J=1.7 Hz), 8.21 (ddd, 1H, J=8.2 Hz, J=J.14, J=1.3 Hz), 8.55 (dd, 1H, J=1.3 Hz, J=1.3 Hz), 8.92 (dd, 1H, J=4.2 Hz, J=1.7 Hz).

2159603

EXAMPLE 13
(REACTION SCHEMES B-1, B)

PREPARATION OF

6-BROMOMETHYL-8-BROMOQUINOLINE

Formula 5, Where R¹ Is Bromomethyl and R² Is Bromo

3.7g (16.66 mmol) of 6-Methyl-8-bromoquinoline was dissolved in 85mL of CCl₄ and 3g of N-bromosuccinamide (16.66 mmol) was added followed by a catalytic amount of azobisisobutyronitrile (AIBN). The reaction mixture was heated at reflux under nitrogen for 1.5 hours and irradiated with a lamp, the cooled and pour into water (100mL). The organic layer was separated and washed with H₂O (100mL) and brine (100mL), dried over MgSO₄, filtered and concentrated to give a brown solid. Crystallization from ethyl acetate/hexane yielded 2.84g (9.44 mmol) of light brown crystals. The filtrate was concentrated and the residue crystallized from the same solvent system. A second crop of light brown crystals (0.77g 2.56 mmol) was obtained. Column chromatography on silica gel of the concentrated filtrate in 20% ethyl acetate/hexanes gave 0.59g (1.96 mmol) of 6-bromomethyl-8-bromoquinoline as a brown solid (4.2g total, 13.95 mmol, 84%), mp 156.2-157.8°.

PREPARATION OF

6-(N-PYRROLIDINYLMETHYL-8-BROMOQUINOLINE

Formula 5, Where R¹ Is Pyrrolidinylmethyl and R² Is Bromo

0.62g (2.1 mmol) of 6-bromomethyl-8-bromoquinoline was slurried in 15 mL of THF and pyrrolidine (0.38 mL, 4.6 mmol) was added dropwise under nitrogen. The reaction mixture was stirred for 1.5h, and then poured into half saturated NaHCO₃ (50mL) and 25 mL EtOAc. The organic layer was washed with H₂O (20mL), and brine (25mL), dried over MgSO₄, filtered and concentrated. Flash chromatography of the residue on silica gel using 5% MeOH/CH₂Cl₂ yielded 0.44g (1.51 mmol, 72%) of 6-(N-pyrrolidinylmethyl)-8-bromoquinoline as a dark oil.

PREPARATION OF

6-(N-PYRROLIDINYLMETHYL-8-(3-NITROPHENYL) QUINOLINE

Formula 5, Where R¹ Is Pyrrolidinylmethyl and R² Is 3-Nitrophenyl

0.32g (1.1 mmol) of 6-(N-pyrrolidinylmethyl)-8-bromoquinoline was dissolved in 10 mL of 1:1 EtOH/benzene under nitrogen. 3-nitrophenyl boronic acid (0.37g, 2.2 mmol), 2M Na₂CO₃ (2.2 mL, 4.4 mmol), and tetrakis(triphenylphosphine)palladium Pd(PPh₃)₄ (0.05g, 0.044 mmol) were added successively and the reaction mixture was refluxed for 4h, then cooled and poured into water (15mL) and extracted with EtOAc (15 mL). The organic layer was washed with water (10 mL) and brine (10mL), dried over MgSO₄, filtered and concentrated. The residue was chromatographed using 10% methanol/ CH₂Cl₂.

2159603

-42-

0.29g (0.87 mmol) of 6-(N-pyrrolidinylmethyl)-8-(3-nitrophenyl)quinoline was obtained as a yellow oil. The oil was dissolved in 15 ml of EtOAc, and the HCl salt was formed with a saturated solution of HCl/EtOAc. The residue was concentrated and crystallized from ethanol/ethyl acetate/ether/hexane to give 0.29g (0.71 mmol, 65%) of 6-(N-pyrrolidinylmethyl)-8-(3-nitrophenyl)quinoline dihydrochloride as yellow crystals, mp 223-225°C.

PREPARATION OF

6-(N-PYRROLIDINONYLMETHYL)-8-BROMOQUINOLINE

Formula 5, Where R¹ Is Pyrrolidinonylmethyl and R² Is Bromo 8-bromo-6-bromomethylquinoline (1.33 mmol) was dissolved in THF/[1,3-dimethyl-3,4,5,6-tetrahydro-2(1H)pyrimidinone (DMPU) and reacted with a solution of NaH (1.6 mmol) and pyrrolidinone (1.6 mmol) at reflux for 24 h to obtain 8-bromo-6-(N-pyrrolidinonylmethyl) quinoline as a yellow oil that was used directly in the next step.

PREPARATION OF

6-(N-PYRROLIDINONYLMETHYL)-8-(3-NITROPHENYL)QUINOLINE

Formula I, Where R¹ Is Pyrrolidinonylmethyl and R² Is 3-Nitrophenyl 8-bromo-6-(N-pyrrolidinonylmethyl) quinoline (1.05 mmol) was reacted with 3-nitroboronic acid (2.1 mmol), 2M Na₂CO₃ (4.2 mmol), and Pd(PPh₃)₄ (0.04 mmol) to obtain 8-(3-nitrophenyl)-6-(N-pyrrolidinonylmethyl) quinoline as white crystals (0.55 mmol, 52%), mp 127.4-128.3°C.

EXAMPLE 14

(REACTION SCHEME C-3)

PREPARATION OF

6-PYRROLYLMETHYL-8-(3-NITROPHENYL)QUINOLINE

Formula I, Where R¹ Is Pyrrolylmethyl and R² Is 3-Nitrophenyl 0.6g (1.75 mmol) of freshly distilled pyrrole was added to a slurry of NaH (0.046g, 1.9 mmol) in 5 mL of dry DMF under nitrogen. The reaction mixture was stirred for 10 min and then 0.6g (1.75 mmol) of 6-bromomethyl-8-(3-nitrophenyl)quinoline, dissolved in 5 mL of DMF, was added to form a dark solution. The solution was stirred at room temperature for 2h, then heated at 80°C for 2h. The reaction mixture was cooled and poured into 150 mL of water, extracted with CH₂Cl₂ (4 x 25 mL). The combined organic layers were washed with water (50 mL), brine (50mL), and dried over MgSO₄. Filtration and concentration provided a solid which was purified by flash chromatography on silica gel using 30% ethyl acetate/hexane. Yield: 0.3g of a yellow oil. The oil was dissolved in 15 mL of ethyl acetate and the HCl salt was formed from ethyl acetate/HCl. The solution was concentrated and the resulting oil was crystallized from ethanol/ether. Yield: 0.26g (0.64 mmol, 37%) of

2159603

-43-

6-pyrrolylmethyl-8-(3-nitrophenyl)quinoline dihydrochloride as yellow crystals, mp 183.2-184.8°C.

PREPARATION OF

6-(PHENYLAMINOMETHYL)-8-(3-NITROPHENYL)QUINOLINE

Formula I, Where R¹ Is Phenylaminomethyl and R² Is 3-Nitrophenyl

0.5g (1.46 mmol) of 6-bromomethyl-8-(3-nitrophenyl)quinoline was dissolved in 10mL of ethanol. 0.15g (1.61 mmol) of aniline and 0.3g (2.2 mmol) of K₂CO₃ was added. The reaction mixture was refluxed under nitrogen for 24h, then poured into water (50 mL) and ethyl acetate (50 mL). The organic layer was separated and washed with water (30 mL) and brine (30 mL), dried over MgSO₄, filtered, concentrated and purified by flash chromatography using 30% ethyl acetate/hexane. An impure yellow oil was obtained which was further purified by preparative TLC using the same solvent system to obtain 0.2g of yellow oil. Crystallization from ethyl acetate/hexane gave 0.1g (0.28 mmol, 19%) of 6-(phenylaminomethyl)-8-(3-nitrophenyl)quinoline as yellow crystals, mp 149.9-150.5°C.

PREPARATION OF

6-(1,2,4-TRIAZOLYLMETHYL)-8-(3-NITROPHENYL)QUINOLINE

Formula I, Where R¹ Is 1,2,4-Triazolylmethyl and R² Is 3-Nitrophenyl

6-Bromomethyl-8-(3-nitrophenyl)quinoline (1.75 mmol) was reacted with 1,2,4-triazole (3.5 mmol), K₂CO₃ (4.38 mmol), and tetrabutylammonium iodide (0.18 mmol) in refluxing ethyl acetate to obtain 6-(1,2,4-triazolylmethyl)-8-(3-nitrophenyl)quinoline (0.91 mmol, 57%) as yellow crystals, mp 160.7-161.5°C.

PREPARATION OF

6-(1,2,4-TRIAZOLYLMETHYL)-8-(3-CHLOROPHENYL)QUINOLINE

Formula I, Where R¹ Is 1,2,4-Triazolylmethyl and R² Is 3-Chlorophenyl

6-Bromomethyl-8-(3-chlorophenyl)quinoline (1.26 mmol) was reacted with a solution of NaH (1.89 mmol) and 1,2,4-triazole (1.89 mmol), in THF for 24h to give 6-(1,2,4-triazolylmethyl)-8-(3-chlorophenyl)quinoline dihydrochloride (0.22 mmol, 18%) as light brown crystals, mp 208.1-208.5°C.

PREPARATION OF

6-(IMIDAZOLYLMETHYL)-8-(3-CHLOROPHENYL)QUINOLINE

Formula I, Where R¹ Is Imidazolylmethyl and R² Is 3-Chlorophenyl

6-Bromomethyl-8-(3-chlorophenyl)quinoline (1.7 mmol) was reacted with a solution of s-BuLi (1.7 mmol) and imidazole (1.87 mmol) in THF at -78°C, then room temperature for 1h to obtain 6-(imidazolylmethyl)-8-(3-chlorophenyl)quinoline dihydrochloride (1.35 mmol, 79 %), mp 65-65.4°C.

2159603 -44-

PREPARATION OF

6 - (IMIDAZOLYLMETHYL) - 8 - (3 - NITROPHENYL) QUINOLINE

Formula I, Where R¹ Is Imidazolylmethyl and R² Is 3-Nitrophenyl

5 6-Bromomethyl-8-(3-nitrophenyl)quinoline (1.28 mmol) was reacted with a solution of n-BuLi (1.92 mmol) and imidazole (1.92 mmol) in THF at -78° C, then room temperature for 24 h to give 6-(imidazolylmethyl)-8-(3-nitrophenyl)quinoline (0.52 mmol, 40%), mp 129.5-130.5°C.

EXAMPLE 15

(REACTION SCHEME C-1)

PREPARATION OF

6 - (4 - FLUOROBENZYL) - 8 - (3 - NITROPHENYL) QUINOLINE

Formula I, Where R¹ Is 4-Fluorobenzyl and R² Is 3-Nitrophenyl

15 0.5g (1.46 mmol) of 6-bromomethyl-8-(3-nitrophenyl)quinoline was dissolved in 15 mL of 1:1 ethanol/benzene. 0.41g (2.9 mmol) of 4-fluorophenyl boronic acid, 3 mL (5.8 mL) 2M Na₂CO₃, and 0.07g (0.06 mmol) Pd(PPh₃)₄ were added. The reaction mixture was refluxed under nitrogen for 20 min, cooled
20 and poured into water (30 mL) and extracted with ethyl acetate (30 mL). The organic layer was washed with water (25 mL) and brine (25 mL), dried over MgSO₄, filtered and concentrated. The residue was purified by flash chromatography using 30% ethyl acetate/ hexane to obtain 0.41g of an impure yellow oil which was further purified by preparative TLC using the same
25 solvent system. 0.33g of a clear oil was obtained which was crystallized from ethyl acetate/hexanes at 0° C to give 0.2g (0.56 mmol, 36%) of 6-(4-fluorobenzyl)-8-(3-nitrophenyl)quinoline as white crystals, mp 97.7-98.5°C.

PREPARATION OF

6 - (4 - METHOXYBENZYL) - 8 - (3 - NITROPHENYL) QUINOLINE

Formula I, Where R¹ Is 4-Methoxybenzyl and R² Is 3-Nitrophenyl

30 6-Bromomethyl-8-(3-nitrophenyl)quinoline (1.17 mmol) was reacted with 4-methoxyboronic acid (2.34 mmol), 2M Na₂CO₃ (4.68 mmol), and Pd(PPh₃)₄ (0.05 mmol) to obtain 6-(4-methoxybenzyl)-8-(3-nitrophenyl)quinoline (0.49 mmol, 42%) as tan crystals, mp 117.5-119.1°C.

EXAMPLE 16

(REACTION SCHEME B-1)

PREPARATION OF

6 - ISOPROPYL - 8 - (3,4 - METHYLENEDIOXYPHENYL) QUINOLINE

Formula I, Where R¹ Is Isopropyl and R² Is 3,4-Methylenedioxyphenyl

40 0.84g (3.36 mmol) of 6-isopropyl-8-bromoquinoline was dissolved in 15 mL of dry THF and cooled to -78°C. s-BuLi (2.7 mL, 3.53mmol, (1.3M/cyclohexane))

2159603

was added dropwise under nitrogen. The reaction mixture was stirred for 5 min and then ZnCl_2 (7 mL, 3.53 mmol, (0.5M/THF)) was added dropwise. The reaction mixture was warmed to room temperature over a period of 1 h. 0.44mL (3.7 mmol) of 1-Bromo-3,4-methylenedioxybenzene was added dropwise followed by 0.19g (0.17mmol) $\text{Pd}(\text{PPh}_3)_4$. The reaction mixture was refluxed for 2.5 h, cooled and poured into water (25 mL) and ethyl acetate (25 mL). The organic layer was washed with water (20 mL) and brine (20 mL), dried over MgSO_4 , filtered and concentrated. The resulting brown oil was purified by flash chromatography using 15% ethyl acetate /hexanes to obtain 0.47g of a pure, clear oil which was crystallized from ethyl acetate/hexanes. Yield: 0.25g (0.85 mmol, 25%) of 6-isopropyl-8-(3,4-methylenedioxy-phenyl)quinoline as white platelets, mp 86.6-88.2°C.

PREPARATION OF

6-ISOPROPYL-8-(3-CYANOPHENYL)QUINOLINE

Formula I, Where R^1 Is Isopropyl and R^2 Is 3-Cyanophenyl

6-Isopropyl-8-bromoquinoline (3.8 mmol) was reacted with 1.3M s-BuLi (3.99 mmol), ZnCl_2 (3.8 mmol), 3-cyanobromobenzene (3.8 mmol), and $\text{Pd}(\text{PPh}_3)_4$ (0.19 mmol) to obtain 6-isopropyl-8-(3-cyanophenyl)quinoline dihydrochloride (1.1 mmol, 29%) as white crystals, mp 194.8-197.6°C.

PREPARATION OF

6-ISOPROPYL-8-(4-METHOXYPHENYL)QUINOLINE

Formula I, Where R^1 Is Isopropyl and R^2 Is 4-Methoxyphenyl

6-Isopropyl-8-bromoquinoline (3 mmol) was reacted with 1.3M s-BuLi (3.03 mmol), ZnCl_2 (3 mmol), 4-methoxyiodobenzene (3.6 mmol), and $\text{Pd}(\text{PPh}_3)_4$ (0.15 mmol). 6-isopropyl-8-(4-methoxyphenyl)quinoline (0.67 mmol, 23%) was obtained as a clear oil.

PREPARATION OF

6-ISOPROPYL-8-(4-TRIFLUOROMETHYLPHENYL)QUINOLINE

Formula I, Where R^1 Is Isopropyl and R^2 Is 4-Trifluoromethylphenyl

6-Isopropyl-8-bromoquinoline (2.7 mmol) was reacted with 1.3M s-BuLi (2.83 mmol), ZnCl_2 (2.83 mmol), 4-trifluoromethyliodobenzene (4.05 mmol), and $\text{Pd}(\text{PPh}_3)_4$ (0.14 mmol) to obtain 6-isopropyl-8-(4-trifluoromethylphenyl)quinoline hydrochloride (0.97 mmol, 36 %) as off-white crystals, mp 167.5-168.4°C.

EXAMPLE 17

(REACTION SCHEME B)

PREPARATION OF

METHYL 3-TRIFLUOROMETHANESULFOXYBENZOATE

Formula 3C, Where R^2 Is Trifluoromethanesulfonyloxy

-46-

10g (65.73 mmol) of Methyl 3-hydroxybenzoate was dissolved in 330 mL of CH_2Cl_2 and cooled to 0°C . 45.8 mL (328.65 mmol) of triethylamine was added to form a light brown solution. Trifluoromethanesulfonic anhydride (triflic anhydride) (16.6 mL, 98.6 mmol) was added via addition funnel under nitrogen over 0.5h to form a dark brown solution. The reaction mixture was poured into a saturated solution of NaHCO_3 (200 mL) and extracted with CH_2Cl_2 (200 mL). The organic layer was washed with water (2 x 100mL) and brine (100 mL), dried over MgSO_4 , filtered, and concentrated. Flash chromatography using 20% ethyl acetate/ hexanes provided a slightly impure brown oil which was distilled (1.2 torr, $92-94.5^\circ\text{C}$) to yield 13.79g (48.52 mmol, 74%) of 3-(trifluoromethanesulfonyloxy)benzoic acid methyl ester (methyl 3-trifluoromethanesulfoxybenzoate) as a yellow liquid.

PREPARATION OF

6-ISOPROPYL-8-(3-CARBOMETHOXYPHENYL)QUINOLINE

Formula I, Where R^1 Is Isopropyl and R^2 Is 3-Methylbenzoate

6-Isopropyl-8-bromoquinoline (4.12 mmol) was reacted with 1.3M s-BuLi (4.33 mmol), ZnCl_2 (4.33 mmol), methyl 3-trifluorosulfoxybenzoate (4.33 mmol), and $\text{Pd}(\text{PPh}_3)_4$ (0.21 mmol) to obtain 6-isopropyl-8-(3-carbomethoxy-phenyl)quinoline hydrochloride (0.56g, 1.64 mmol, 40%) which was crystallized from ethanol/ether/hexanes to yield light yellow crystals, mp $166.5-167.6^\circ\text{C}$.

EXAMPLE 18

(REACTION SCHEME C-1)

PREPARATION OF

6-CYANOMETHYL-8-(3-NITROPHENYL)QUINOLINE

Formula I, Where R^1 Is Cyanomethyl and R^2 Is 3-Nitrophenyl

1g (2.91 mmol) of 6-Bromomethyl-8-(3-nitrophenyl)quinoline was dissolved in 5mL of CH_2Cl_2 . To this solution was added dropwise 0.78g (2.91 mmol) of tetrabutylammonium cyanide dissolved in 5 ml of CH_2Cl_2 over 5 min. The reaction mixture was stirred for 1h at room temperature then refluxed overnight. An additional 0.39g (1.45 mmol) of tetrabutylammonium cyanide was added and the reaction refluxed for 3 more hours. The reaction was then concentrated and ethyl acetate (30 mL) and water (30 mL) were added. The organic layer was washed with water (2 x 30 mL), and brine (30 mL). CH_2Cl_2 (50 mL) was added to the organic layer to solubilize the suspended solids and the solution was then dried over MgSO_4 , filtered and concentrated. The residue was dissolved in a minimal amount of CH_2Cl_2 , absorbed on silica gel, and placed on top of a silica gel column and eluted with 50% ethyl acetate/hexanes. Yield 0.6g (2.07 mmol, 71%) of 6-cyanomethyl-8-(3-nitrophenyl)quinoline as a yellow solid, mp $178.0-180.5^\circ\text{C}$.

2159603

-47-

PREPARATION OF

6-[1-(4-CHLOROPYRIDAZINYL)-1-CYANOMETHYL]-8-(3-NITROPHENYL)QUINOLINE
Formula I, Where R¹ Is [1-(4-Chloropyridazinyl)-1-cyanomethyl] and R² Is 3-Nitrophenyl

0.45g (1.56 mmol) of 6-cyanomethyl-8-(3-nitrophenyl)quinoline and 0.49 (3.28 mmol) of 1,4-dichloropyridazine were dissolved in 15 mL of dry DMF under nitrogen and cooled to 0 C. NaH (0.078g 3.28 mmol) was added portionwise and the reaction stirred at 0 C for 45 min and then 30 min at room temperature. The reaction mixture was poured into CH₂Cl₂ (150 mL) and 150 mL of half saturated NH₄Cl was added. The organic layer was separated and the aqueous layer was washed with CH₂Cl₂ (100 mL). The combined organic layers were washed with water (2 x 100 mL), and brine (100 mL), dried over MgSO₄, filtered and concentrated. Chromatography using 50% ethyl acetate/hexanes yielded 0.51g (1.27 mmol, 81%) of 6-(1-(4-chloropyridazinyl)-1-cyanomethyl)-8-(3-nitrophenyl)quinoline as an orange foam.

PREPARATION OF

6-PYRIDAZINONYLMETHYL)-8-(3-NITROPHENYL)QUINOLINE

Formula I, Where R¹ Is Pyridazinonylmethyl] and R² Is 3-Nitrophenyl

0.4g (1 mmol) of 6-(1-(4-chloropyridazine)-1-cyanomethyl)-8-(3-nitrophenyl)quinoline was dissolved in 5 mL acetic acid, 5 mL water, and 10 mL conc. hydrochloric acid. The reaction mixture was refluxed for 24h, and then concentrated. The residue was dissolved in water (25 mL), saturated NaHCO₃ (150 mL) and ethyl acetate (100 mL) were added. The organic layer was washed with water (100 mL) and brine (100 mL), dried over MgSO₄, filtered and concentrated to obtain 0.27g of a brown solid. The residue was purified by preparative TLC using 5% MeOH/ CH₂Cl₂. Yield: 0.25g (0.7 mmol, 70%) of 6-(4-pyridazinonylmethyl)-8-(3-nitrophenyl)quinoline as an off-white solid, mp 199.5-202.0° C.

EXAMPLE 19

(REACTION SCHEMES A-1, B)

PREPARATION OF

4-NITRO-1-CYCLOPENTYLIDINYL BENZENE

Formula 1a, Where R Is Cyclopentyl

5g (33.42 mmol) of Cyclopentyltriphenylphosphine bromide was slurried in 100mL of dry THF and 18.4 mL of 1.8M PhLi (33.09 mmol) was added over 5 min. The reaction mixture was stirred for 1h at room temperature, then refluxed for 15 min, and cooled to room temperature. 5g (33.09 mmol) of 4-nitrophenyl carboxaldehyde in 40 mL of dry THF was added dropwise. The reaction mixture was stirred at 40° C for 24 h, then poured into water (100 mL) and ethyl acetate (100 mL). The aqueous layer was extracted with ethyl acetate (3 x 50 mL). The combined organic layers were dried over MgSO₄,

-48-

filtered, and concentrated. Flash chromatography using 50% ethyl acetate/hexanes yielded 4.7 g (23.13 mmol) of 4-nitro-1-cyclopentylidinybenzene as an impure black oil.

5

**PREPARATION OF
CYCLOPENTYLIDINYLANILINE**

Formula 1b, Where R Is Cyclopentyl

10

4.7g of 4-nitro-1-cyclopentylidinybenzene was dissolved in ethanol (100 mL) and catalytically hydrogenated (Pd/C) under 1 atm of hydrogen for 24h. The reaction mixture was filtered through Celite, concentrated to an orange semi-solid, and chromatographed using 10% ethyl acetate to obtain 2.14g (12.35 mmol) of 4-cyclopentylidinyaniline as a yellow semi-solid.

15

**PREPARATION OF
4-CYCLOPENTYLMETHYLANILINE**

Formula 2a, Where R Is Cyclopentyl

20

1.83g (10.32 mmol) of 4-cyclopentylidinyaniline was dissolved in ethanol (50 mL) and catalytically hydrogenated (PtO₂) under 1 atm of hydrogen for 30 min. The reaction mixture was filtered through Celite and concentrated. The residue was chromatographed using 20% ethyl acetate/ hexanes to afford 1.52 g of a yellow oil as a mixture of starting material and product. The yellow oil was dissolved in ethanol (25 mL) and catalytically hydrogenated (PtO₂) under 1 atm of hydrogen for 5h. Filtration through Celite, concentration, and chromatography using 20% ethyl acetate/ hexanes gave 1.52g (8.67 mmol 84%) of 4-cyclopentylmethylaniline as a clear oil.

25

**PREPARATION OF
2-BROMO-4-CYCLOPENTYLMETHYLANILINE**

Formula 3a, Where R Is Cyclopentyl and X is Bromo

30

1.07g (6.1 mmol) of 4-cyclopentylmethylaniline was dissolved in DMF (2.5 mL) and placed under nitrogen. 1.09g (6.1 mmol) of N-bromosuccinamide, dissolved in DMF (2.5 mL), was added dropwise. The reaction mixture was stirred for 5h, then poured into water (100 mL), and extracted with ether (3 x 25 mL). The combined ether extracts were dried over MgSO₄ and filtered. Concentration and flash chromatography on silica gel using 10% ethyl acetate/hexanes provided 0.98g (3.86 mmol, 63%) of 2-bromo-4-cyclopentylmethylaniline as a light brown oil.

35

PREPARATION OF

40

6-CYCLOPENTYLMETHYL-8-BROMOQUINOLINE

Formula 5, Where R Is Cyclopentylmethyl and X is Bromo

0.66g (2.6 mmol) of 2-bromo-4-cyclopentylmethylaniline was slurried in 0.094g (0.34 mmol) Iron (II) sulfate heptahydrate, 0.17 mL (1.66mmol) nitrobenzene, and 1g (10.4 mmol) of glycerol, and heated to 115°C under

2159603

nitrogen. H₂SO₄ (0.55 mL) was added dropwise and the reaction mixture was heated to 165°C, stirred for 2h and then poured into saturated NaHCO₃ (300 mL) and ethyl acetate (50 mL). The solution was filtered through glass wool and the filtrate was extracted with ethyl acetate (2 x 50mL). The combined
5 extracts were dried over MgSO₄ and filtered. Concentration and flash chromatography (10% EtOAc/hexanes) yielded 0.58g (2 mmol, 77%) of 6-cyclopentylmethyl-8-bromoquinoline as a yellow oil.

PREPARATION OF

6-CYCLOPENTYLMETHYL-8-(3-CHLOROPHENYL)QUINOLINE

Formula I, Where R¹ Is Cyclopentylmethyl and R² is 3-Chlorophenyl
0.19g (0.65 mmol) of 6-Cyclopentylmethyl-8-bromoquinoline was dissolved in 6.5 mL of 1:1 ethanol/ benzene under nitrogen. 0.2g (1.3 mmol) of 3-chloroboronic acid, 1.3 mL (2.6 mmol) of 2M Na₂CO₃, and 0.03g (0.026 mmol)
15 of Pd(PPh₃)₄ were added successively. The reaction mixture was refluxed for 3h, then cooled and poured into water (25 mL) and ethyl acetate (25 mL). The organic extract was dried over MgSO₄ and filtered. Flash chromatography on silica gel using 20% ethyl acetate/hexanes yielded 0.17g of impure product which was purified further by preparative TLC in the same
20 solvent system to obtain 0.16g yellow oil. Formation of the HCl salt with saturated HCl/EtOAc and crystallization of the resulting residue from EtOH/EtOAc/ether yielded 0.14 g (0.4 mmol, 60%) of 6-cyclopentylmethyl-8-(3-chlorophenyl)quinoline hydrochloride as white crystals, mp 179.3-183.7°C.

PREPARATION OF

6-CYCLOPENTYLMETHYL-8-(3-NITROPHENYL)QUINOLINE

Formula I, Where R¹ Is Cyclopentylmethyl and R² is 3-Nitrophenyl
Similarly, 6-Cyclopentylmethyl-8-bromoquinoline (0.55 mmol) was reacted
30 with 3-chloroboronic acid (1.1 mmol), 2M Na₂CO₃ (2.2 mmol), and Pd(PPh₃)₄ (0.02 mmol) to obtain 6-cyclopentylmethyl-8-(3-nitrophenyl)quinoline hydrochloride (0.42 mmol, 77 %), as tan crystals from EtOH/EtOAc/Et₂O, mp 185.8-190.4°C.

EXAMPLE 20

(REACTION SCHEMES B-3, B)

PREPARATION OF

6-METHOXY-8-AMINOQUINOLINE

Formula 5, Where R¹ Is Methoxy and X is Amino
4 g (19.6 mmol) of commercially available 6-methoxy-8-nitroquinoline was dissolved in ethanol (100 mL) and THF (25 mL) and catalytically
40 hydrogenated (Pd/C, 1 atm H₂) for 5h. The reaction mixture was filtered through Celite and concentrated. Flash chromatography using 5% MeOH/ CH₂Cl₂

2159603

-50-

yielded an impure product which was re-chromatographed in 50% EtOAc/hexanes to give 2.76g (15.84 mmol, 81%) of 6-methoxy-8-aminoquinoline as a yellow oil.

5

PREPARATION OF

6-METHOXY-8-BROMOQUINOLINE

Formula 5, Where R¹ Is Methoxy and X is Bromo

1.25 g (7.18 mmol) of 6-methoxy-8-aminoquinoline was mixed with 48% HBr (6 mL) and water (6 mL) to form an orange slurry. The mixture was then cooled to 0°C and a solution of 5 g of NaNO₂ (9.3 mmol) in 5 mL of water was added dropwise. The resulting brown solution was stirred for 15 min and then added to a solution of 1.24 g CuBr (8.6 mmol) in 15 mL of 48% HBr with stirring at 75°C. The reaction mixture was stirred at 75°C for 5.5h and was then made basic with 10% NaOH and filtered through filter paper. The filtrate was partitioned between water (50 mL) and EtOAc (50 mL) and extracted with EtOAc (2 x 50 mL). The combined organic extracts were dried over MgSO₄, filtered, and concentrated to give 0.6 g of a dark oil which was purified by preparative TLC (20% EtOAc/hexanes) to afford 0.36g (1.5 mmol, 21%) of 6-methoxy-8-bromoquinoline as a tan solid, mp 64.5-65.6°C.

20

PREPARATION OF

6-HYDROXY-8-BROMOQUINOLINE

Formula 5, Where R¹ Is Hydroxy and X is Bromo

0.26g (1.1 mmol) of 6-methoxy-8-bromoquinoline was dissolved in CH₂Cl₂ (11 mL) and cooled to -78°C. 2.7 mL (2.75 mmol) of BBr₃ (1M in CH₂Cl₂) was added dropwise to form a yellow slurry. The reaction mixture was stirred for 10 min at -78°C, the bath was removed and the reaction mixture was allowed to warm to room temperature, stirred for 1.5 h and then MeOH (20 mL) was added to quench the reaction. The reaction mixture was concentrated under reduced pressure, 20 mL of MeOH was added and again concentrated (repeated 2x). The residue was partitioned between EtOAc and water. The organic layer was washed 2x with NaOH (0.5 N). The base extracts were neutralized with saturated NH₄Cl and extracted with EtOAc (2 x 25 mL). The organic layers were washed with brine, dried over MgSO₄, filtered, and concentrated to yield 0.11g (0.49 mmol, 45 %) of 6-hydroxy-8-bromoquinoline as an off-white solid, mp 249.5-250.6°C.

35

PREPARATION OF

6-CYCLOPENTYLOXY-8-BROMOQUINOLINE

Formula 5, Where R¹ Is Cyclopentyloxy and X is Bromo

0.2g (0.89 mmol) of 6-hydroxy-8-bromoquinoline was dissolved in DMF (5 mL). 0.25g (1.78 mmol) of powdered K₂CO₃ and 0.2 mL (1.78 mmol) cyclopentylbromide were added, and reaction mixture was heated at 75°C for 1.5h. The reaction mixture was then cooled and poured into water (20 mL)

40

2159603

and extracted with ether (20 mL). The ether layer was washed with water (30 mL) and brine (30 mL). The aqueous layers were re-extracted with ether (20 mL) and the combined organic layers were dried over MgSO_4 , filtered and concentrated to obtain 0.26g (0.89 mmol, 100%) of 6-cyclopentyloxy 8-bromoquinoline as a crude yellow solid, mp 76.2-79.2°C.

PREPARATION OF

6-CYCLOPENTYLOXY-8-(3-NITROPHENYL)QUINOLINE

Formula I, Where R^1 Is Cyclopentyloxy and R^2 is 3-Nitrophenyl

0.22g (0.75 mmol) of 6-cyclopentyloxy-8-bromoquinoline was dissolved in 7.5 mL of 1:1 EtOH/benzene and 0.25g (1.5 mmol) 3-nitroboronic acid, 1.5 mL (3 mmol) 2M Na_2CO_3 , and 0.035g (0.3 mmol) $\text{Pd}(\text{PPh}_3)_4$ were added successively. The reaction mixture was refluxed for 2h under nitrogen, then partitioned between water/EtOAc. The organic layer was washed with water, brine, dried over MgSO_4 , and filtered. Concentration and purification by preparative TLC using 15% EtOAc/hexanes provided 0.2g of a yellow oil. The hydrochloride salt was formed with saturated HCl/EtOAc and crystallized from EtOH/EtOAc/ether. Yield: 0.21g (0.56 mmol, 75%) of 6-cyclopentyloxy-8-(3-nitrophenyl)quinoline as white crystals, mp 190-191.4°C.

EXAMPLE 21

By following the procedures in Examples 1-20, other 6,8-disubstituted quinolines within the scope of this invention can be prepared.

For example, the following 6,8-disubstituted quinoline compounds of formula I were prepared by following the above described procedures:

6-isopropyl-8-(3-nitrophenyl)quinoline, (hydrochloride),
mp 204.5-216 °C;

4-pyridylmethyl-8-(3-nitrophenyl)quinoline, (dihydrochloride),
mp 238-240°C;

6-[1-(1,2,4-triazolyl)]-8-(3-nitrophenyl)quinoline, mp 160.7-162.5°C;

6-anilinomethyl-8-(3-nitrophenyl)quinoline, mp 149.9-150.5°C;

6-(4-pyridazinonylmethyl)-8-(3-nitrophenyl)quinoline, mp 199.5-202°C;

6-(2-pyrrolidinonylmethyl)-8-(3-nitrophenyl)quinoline, mp 127.4-128.3°C.

6-cyclopentylmethyl-8-(3-nitrophenyl)quinoline, (hydrochloride),
mp 186.3-191.2°C.

6-imidazolylmethyl-8-(3-nitrophenyl)quinoline, mp 129.5-130.5°C.

6-cyclohexyl-8-(3-nitrophenyl)quinoline, (hydrochloride),
mp 188.5-194.8°C.

6-cyclopentyloxy-8-(3-nitrophenyl)quinoline, (hydrochloride),
mp 190-191.4°C.

6-ethyl-8-(3-nitrophenyl)quinoline, (hydrochloride),
mp 193.1-193.6°C.

- 6-n-propyl-8-(3-nitrophenyl)quinoline, (hydrochloride),
mp 208.5-209.7°C.
- 6-n-butyl-8-(3-nitrophenyl)quinoline, (hydrochloride),
mp 194.1-198.5°C.
- 5 6-t-butyl-8-(3-nitrophenyl)quinoline, (hydrochloride),
mp 214-214.8°C;
- 6-n-pentyl-8-(3-nitrophenyl)quinoline, (hydrochloride),
mp 175.9-177.9°C;
- 6-(4-fluorobenzyl)-8-(3-nitrophenyl)quinoline, mp 97.7-98.5°C.
- 10 6-pyrrolidinyl-8-(3-nitrophenyl)quinoline, (dihydrochloride)
mp 223-225°C.
- 4-pyridylmethyl-8-(3-chlorophenyl)quinoline, (dihydrochloride),
mp 243.0-246.4°C;
- 6-[1-(1,2,4-triazolyl)]-8-(3-chlorophenyl)quinoline, (dihydrochloride),
15 mp 208.1-208.5°C;
- 6-imidazolylmethyl-8-(3-chlorophenyl)quinoline, (dihydrochloride),
mp 64-64.5°C.
- 6-ethyl-8-(3-chlorophenyl)quinoline, (hydrochloride),
mp 184.8-185.9°C.
- 20 6-n-propyl-8-(3-chlorophenyl)quinoline, (hydrochloride),
mp 206.4-210.4°C.
- 6-n-butyl-8-(3-chlorophenyl)quinoline, (hydrochloride),
mp 202.3-208.7°C.
- 6-t-butyl-8-(3-chlorophenyl)quinoline, (hydrochloride),
25 mp 197.5-198.5°C;
- 6-n-pentyl-8-(3-chlorophenyl)quinoline, (hydrochloride),
mp 182.2-183.6°C;
- 6-cyclohexyl-8-(3-chlorophenyl)quinoline, (hydrochloride),
mp 197.7-203.7°C.
- 30 6-(1-hydroxy-1-methylethyl)-8-(3-chlorophenyl)quinoline, (hydrochloride),
mp 171.2-171.9°C.
- 6-isopropyl-8-(3,4-methylenedioxyphenyl)quinoline, (hydrochloride),
mp 86.6-88.2°C.
- 6-isopropyl-8-(3-carbomethoxyphenyl)quinoline, (hydrochloride),
35 mp 166.5-167.6°C.
- 6-n-propyl-8-phenylquinoline, (hydrochloride), mp 168-169°C.
- 6-isopropyl-8-phenylquinoline, (hydrochloride), mp 155-158.9°C.
- 6-n-pentyl-8-phenylquinoline, (hydrochloride), mp 151.5-152.3°C.
- 6-isopropyl-8-(4-trifluoromethylphenyl)quinoline, (hydrochloride),
40 mp 167.5-168.6°C.
- 6-isopropyl-8-(3-cyanophenyl)quinoline, (hydrochloride),
mp 206.5-207.6°C.

EXAMPLE 22

Determination of Potency and Selectivity
of Inhibitors for PDE IV5 **Preparation of Human Platelet Phosphodiesterase (PDE III)**

Platelet high-affinity cAMP PDE (PDE III) was obtained from human blood in accordance with previously described procedures described in *Mol. Pharmacol.* 20:302-309, Alvarez, R., Taylor, A., Fazarri, J.J., and Jacobs, J.R. (1981).

10 Blood was collected into evacuated tubes containing EDTA (7.7 mM, final concentration). PRP was obtained by centrifuging the blood in polycarbonate tubes at 200 x g for 15 min at 4°C. A platelet pellet was resuspended in a volume of buffer A (0.137 M NaCl, 12.3 mM Tris-HCl buffer, pH 7.7, containing 1 mM MgCl₂). The hypotonically-lysed platelet suspension
15 was centrifuged at 48,000 x g for 15 min and the supernatant was saved. The pellets were frozen on dry ice and briefly thawed at 22°C. The supernatant was combined with the pellet fraction and the resulting suspension was centrifuged at 48,000 x g for 30 min. The supernatant fraction was stored in 0.5 mL aliquots at -20°C and used as the soluble
20 PDE. Enzyme activity was adjusted to 10-20% hydrolysis after 10 minutes of incubation by dilution with 10mM cold Tris-HCl buffer, pH7.7.

Preparation of Human Lymphocyte Phosphodiesterase (PDE IV)

Human B cell line (43D) were cultured at 37°C in 7% CO₂ in RPMI 1640
25 with L-glutamine and 10% Nu-Serum. Prior to the assay ~1.5x10⁸ cells were centrifuged at 1000 rpm for 10 minutes in a table top clinical centrifuge. The pellet was resuspended in 2-3 mL of 45 mM Tris-HCl buffer, pH 7.4. The suspension was homogenized and centrifuged at 12,000 x g at 4°C for 10 minutes. The supernatant was diluted to 28 mL with Tris-HCl buffer and
30 used directly in the assay or stored at -20°C. The final concentration of DMSO in the PDE incubation medium was 1%. Nitrazozone was included in each assay (10 and 100µM) as a reference standard.

Human Platelet cAMP Phosphodiesterase Assay

35 The phosphodiesterase incubation medium contained 10 mM Tris-HCl buffer, pH 7.7, 10 mM MgSO₄, 0.1-1µM [³H]-AMP (0.2 µCi) in a total volume of 1.0 mL. Following addition of the enzyme, the contents were mixed and incubated for 10 min at 30°C. The reaction was terminated by immersing the tubes in a boiling-water bath for 90 sec. After the tubes were cooled in
40 an ice-water bath, 0.1 mL (100µg) of 5'-nucleotidase from snake venom (Crotalus atrox, Sigma V-7000) was added to each tube. The contents were mixed and incubated for 30 min at 30°C. The nucleotidase reaction was terminated by immersing the tubes in a boiling water bath for 60 sec. Labeled adenosine was isolated from alumina columns according to the method

-54-

described in *Anal. Biochem.*, 52:505-516 (1973), Filburn, C.R., and Karn, J.. Assays were performed in triplicate. Hydrolysis of cAMP ranged from 10-20%. Test compounds were dissolved in DMSO. The final concentration of DMSO in the phosphodiesterase assay was 1% when tested with compounds up to 0.1 mM. When tested at 1 mM the DMSO concentration was 10% and this activity was compared to control PDE activity in the presence of 10% DMSO.

PDE III Activity

Compound I IC₅₀: 53 μ M

Compound I is 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline.

Human Lymphocyte cAMP Phosphodiesterase Assay

The phosphodiesterase incubation medium contained 40 mM Tris-HCl buffer, pH 7.7, 0.1 mM MgSO₄, 3.75 mM mercaptoethanol, and 0.1-1.0 μ M [³H] cAMP (0.2 μ Ci) in a total volume of 1.0 mL. The reaction was performed and processed according to the procedure used (above) for human platelet PDE. The final concentration of DMSO was 1%.

The representative compounds of the present invention exhibit potency and selectivity as inhibitors of PDE IV when tested by the human platelet cAMP phosphodiesterase assay and the human lymphocyte cAMP phosphodiesterase assay.

Inhibition of Human Lymphocyte PDE IV

Compound I	IC ₅₀ :	0.023 nM
Compound II	IC ₅₀ :	0.11 nM
Compound III	IC ₅₀ :	0.063 nM

Compound I is the compound of Formula I where R¹ is 4-pyridylmethyl and R² is 3-nitrophenyl, namely 6-(4-pyridylmethyl)-8-(3-nitrophenyl)quinoline.

Compound II is the compound of Formula I where R¹ is 4-pyridylmethyl and R² is 3-chlorophenyl, namely 6-(4-pyridylmethyl)-8-(3-chlorophenyl)quinoline.

Compound III is the compound of Formula I where R¹ is isopropyl and R² is 3-nitrophenyl, namely 6-isopropyl-8-(3-nitrophenyl)quinoline.

EXAMPLE 23

Determination of Immunosuppressive Activity Utilizing Responses of Human Peripheral Blood Lymphocytes to Mitogen

This procedure is a modification of a procedure initially described by Greaves, et al. ["Activation of human T and B lymphocytes by polyclonal mitogens," *Nature*, 248, 698-701 (1974)].

Human mononuclear cells (PBL) were separated from heparinized whole blood by density gradient centrifugation in Ficoll-Paque (Pharmacia). After washing, 5×10^4 cells/well were cultured in microtiter plates with minimal essential media supplemented with 1% human serum, gentamicin, sodium bicarbonate, 2-mercaptoethanol, glutamine, non-essential amino acids, and sodium pyruvate. The mitogen concanavalin A (Sigma) was used at a concentration of $2 \mu\text{g/ml}$. Test materials were tested at concentrations between 10^{-4} and 10^{-10} M, by addition to the culture at time 0. Cultures were set up in quadruplicate and incubated at 37°C in a humidified atmosphere with 5% CO_2 for 48 hours. A pulse of $1.0 \mu\text{Ci/well}$ of ^3H -thymidine was added for the last 4 hours. Cells were collected on glass fiber filters with an automatic harvester and radioactivity was measured by standard scintillation procedures. The 50% inhibitory concentration (" IC_{50} ") for mitogenic stimulation was determined graphically.

The representative compounds of the present invention showed immunosuppressive activity when tested by this method.

EXAMPLE 24

Determination of Immunosuppressive Activity

Utilizing The Hemolytic Plaque Forming Cell Assay

This procedure is a modification of "The agar plaque technique for recognizing antibody producing cells," a procedure initially described by Jerne, et al. [*Cellbound Antibodies*, Amos and Kaprowski editors (Wistar Institute Press, Philadelphia, 1963) p. 109].

Groups of 5-6 adult C3H female mice were sensitized with 1.25×10^8 sheep red blood cells (SRBC) and simultaneously treated with an oral dosage form of the test material in an aqueous vehicle. Animals in a control group received the same volume of vehicle. Four days after SRBC inoculation, spleens were dispersed in glass homogenizers. The number of nucleated cells (WBC) was determined and the spleen cell suspension was mixed with SRBC, guinea pig complement and agar solution at 0.5% concentration. Aliquots of the above mixture (0.1 mL) were dropped on four separate quadrants of a Petri dish and were covered with cover slips. After two hours incubation at 37°C , areas of hemolysis around plaque-forming cells (PFC) were counted with a dissecting microscope. Total WBC/spleen, PFC/spleen and PFC/ 10^6 WBC (PPM) were calculated for each mouse spleen. Geometric means of each treatment group were then compared with the vehicle-treated control group.

The representative compounds of the present invention showed immunosuppressive activity when tested by this method.

EXAMPLE 25**Determination of Anti-Inflammatory Activity Utilizing
Arachidonic Acid-Induced Ear Edema (AAEE) in the Mouse**

This procedure is a modification of a procedure described by Young et al., *J. Invest. Derm.*, 82:367-371 (1984).

Female Charles River ICR mice 23-27 grams were administered 0.2 mL of test material. The mice were challenged with 20 μ l of arachidonic acid applied topically to the ear. One hour after challenge, the weight of an 8 mm disc was determined. The mean increase in ear plug weight was calculated.

Materials with anti-inflammatory activity inhibit the increase in ear plug weight.

The representative compounds of the present invention exhibited anti-inflammatory activity when tested by this method.

Anti-inflammatory Activity (AAEE)

Compound I	ED ₅₀	0.01mg/kg
Compound II	ED ₅₀	0.2mg/kg
Compound III	ED ₅₀	4.5mg/kg

EXAMPLE 26**Determination of Anti-Inflammatory
Activity Utilizing Adjuvant-Induced
Arthritis In The Rat**

This procedure is a modification of a procedure initially described by Pearson, C.M., *Proc. Soc. Exp. Biol. Med.*, 91:95-101 (1956).

Female Charles River albino rats weighing 160-180 g received 0.1 mL of a suspension in paraffin oil of heat-killed *Mycobacterium butyricum* (10 mg/ml) by means of an intradermal injection into the proximal 1/4 of the tail on day 0. Beginning on day 1, the test material was administered orally in an aqueous vehicle (0.5 mL/dose) once each day for 17 days. On day 18 the intensity of the swelling of the four foot pads and tail was determined utilizing a scoring system in which the swelling in the four paws was scored 0-4 for each paw and the tail swelling was scored 0-3, such that the total maximum score was 19.

The representative compounds of the present invention exhibited anti-inflammatory activity when tested by this method.

EXAMPLE 27**Determination of Activity Towards****Autoimmune Disease Utilizing Survival of MRL/lpr Mice**

MRL/lpr mice develop a multisystemic disease characterized by glomerulonephritis, arthritis, arteritis, lymphoid hyperplasia. The length

of survival of mice with this disease is approximately one-third that of non-disease developing MRL/n mice. These mice have a high incidence of autoantibodies and the disease process is considered autoimmune in nature as described by Theofilopoulos, et al., *Advances in Immunology*, 37:269-390 (1985).

The representative compounds of the present invention significantly extended the lifespan of the MRL/lpr mice.

EXAMPLE 28

Determination of Analgetic Activity

Utilizing Phenylquinone-Induced Stretching in the Mouse

This procedure is a modification of a procedure described by Hendershot, et al. *J. Pharmacol. Exp. Ther.*, 125:237-240 (1959).

Groups of 8 Female CD-1 mice were administered test materials orally in an aqueous vehicle. At various times following administration of test materials, 0.25 mL of a 0.02% solution of phenylquinone was administered intraperitoneally. The number of stretches for each animal was enumerated over a ten minute period following the phenylquinone administration. Analgetic activity was determined by inhibition of the mean number of stretches.

The representative compounds of the present invention showed analgetic activity when tested by this method.

EXAMPLE 29

Capsule Formulation

This example illustrates the preparation of a representative pharmaceutical formulation for oral administration containing an active compound of Formula I, e.g., 6-isopropyl-8-(3-nitrophenyl)quinoline.

Ingredients	Quantity (mg/capsule)
Active compound	200
lactose, spray-dried	148
magnesium stearate	2

The above ingredients are mixed and introduced into a hard-shell gelatin capsule.

Other compounds of Formula I, such as those prepared in accordance with Examples 1-20 can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 30

Oral Formulation

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of Formula I, e.g., 6-isopropyl-8-(3-nitrophenyl)quinoline.

-58-

An suspension for oral administration is prepared having the following composition:

	Ingredients	Quantity
5	Active compound	1.0 g
	fumaric acid	0.5 g
	sodium chloride	2.0 g
	methyl paraben	0.1 g
	granulated sugar	25.5 g
10	sorbitol (70% solution)	12.85 g
	Veegum K (Vanderbilt Co.)	1.0 g
	flavoring	0.035 mL
	colorings	0.5 mg
	distilled water	q.s. to 100 mL

Other compounds of Formula I, such as those prepared in accordance with Examples 1-20 can be used as the active compound in the preparation of the orally administrable formulations of this example.

EXAMPLE 31

Tablet Formulation

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of Formula I, e.g., 6-isopropyl-8-(3-nitrophenyl)quinoline.

A tablet for oral administration is prepared having the following composition:

	Ingredients	Quantity (mg/tablet)
	Active compound	400
30	corn starch	50
	lactose	145
	magnesium stearate	5

The above ingredients are mixed intimately and pressed into single scored tablets.

Other compounds of Formula I, such as those prepared in accordance with Examples 1-20 can be used as the active compound in the preparation of the tablet formulations of this example.

EXAMPLE 32

Injectable Formulation

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of Formula I, e.g., 6-isopropyl-8-(3-nitrophenyl)quinoline.

-59-

An injectable preparation is prepared having the following composition:

	Ingredients	Quantity
5	Active compound	0.2 g
	water (distilled, sterile)	q.s. to 20.0 mL

Other compounds of Formula I, such as those prepared in accordance with Examples 1-20 can be used as the active compound in the preparation of the injection administrable formulations of this example.

EXAMPLE 33

Suppository Formulation

This example illustrates the preparation of a representative pharmaceutical formulation containing an active compound of Formula I, e.g., 6-isopropyl-8-(3-nitrophenyl)quinoline.

A suppository totalling 2.5 grams is prepared having the following composition:

	Ingredients	Quantity
20	Active compound	500 mg
	Witepsol H-15 [®]	q.s. to 2.5 g

(*triglycerides of saturated vegetable fatty acid; a product of Riches-Nelson, Inc., New York, N.Y.).


Other compounds of Formula I, such as those prepared in accordance with Examples 1-20 can be used as the active compound in the preparation of the suppository formulations of this example.

TOXICOLOGY

No serious toxicological effects were observed in the above described assays.

What is claimed is:

1. A compound of the formula



Formula I

wherein:

R^1 is independently selected from lower-alkyl, cycloalkyl, cycloalkyl lower-alkyl, lower-alkoxy, (lower-alkyl)hydroxymethyl, aryl, arylmethyl, pyridylmethyl,

where aryl, arylmethyl and pyridylmethyl are unsubstituted or independently mono, di or tri substituted with hydrogen, hydroxy, thiol, amino, halo, nitro, lower-alkylthio, lower-alkoxy, mono-lower-alkylamino, di-lower-alkylamino, hydroxycarbonyl, lower-alkoxycarbonyl, hydroxysulfonyl, lower-alkoxysulfonyl, lower-alkylsulfonyl, lower-alkylsulfinyl, trifluoromethyl, cyano, tetrazoyl, carbamoyl, lower-alkylcarbamoyl, and di-lower-alkylcarbamoyl; and

R^2 , R^3 , R^4 , R^5 and R^6 are independently selected from hydrogen, hydroxy, thiol, amino, halo, nitro, lower-alkylthio, lower-alkoxy, mono-lower-alkylamino, di-lower-alkylamino, hydroxycarbonyl, lower-alkoxycarbonyl, hydroxysulfonyl, lower-alkoxysulfonyl, lower-alkylsulfonyl, lower-alkylsulfinyl, trifluoromethyl, cyano, tetrazoyl, carbamoyl, lower-alkylcarbamoyl, and di-lower-alkylcarbamoyl, provided that when R^1 is methoxy, R^4 is not amino or nitro;


or a pharmaceutically acceptable ester, ether, N-oxide or salt thereof.

2. The compound of claim 1 wherein R^1 is a pyridylmethyl group.
3. The compound of claim 2 wherein R^1 is 4-pyridylmethyl.
4. The compound of claim 1 wherein R^1 is a lower alkyl group.
5. The compound of claim 4 wherein R^1 is isopropyl.
6. The compound of claim 1 wherein R^3 is selected from the group

consisting of chloro, bromo, fluoro, iodo, nitro, hydroxycarbonyl, lower-alkoxycarbonyl, trifluoromethyl and cyano.

7. The compound of claim 6 wherein R^3 is nitro.
8. The compound of claim 6 wherein R^3 is chloro.
9. The compound of claim 1 wherein R^3 and R^4 are selected from the group consisting of chloro, bromo, fluoro, iodo, nitro, hydroxycarbonyl, lower-alkoxycarbonyl, trifluoromethyl and cyano.
10. The compound of claim 9 wherein R^3 is chloro and R^4 is fluoro.
11. The compound of claim 1 wherein R^2 , R^4 , R^5 and R^6 are hydrogen.
12. The compound of claim 1 wherein R^1 is isopropyl, R^3 is selected from the group consisting of chloro, bromo, fluoro, iodo, nitro, hydroxycarbonyl, lower-alkoxycarbonyl, trifluoromethyl and cyano, and R^2 , R^4 , R^5 and R^6 are hydrogen.
13. The compound of claim 12 wherein R^3 is nitro.
14. The compound of claim 1 wherein R^1 is 4-pyridylmethyl, R^3 is selected from the group consisting of chloro, bromo, fluoro, iodo, nitro, hydroxycarbonyl, lower-alkoxycarbonyl, trifluoromethyl and cyano, and R^2 , R^4 , R^5 and R^6 are hydrogen.
15. The compound of claim 14 wherein R^3 is nitro.
16. The compound of claim 1 wherein R^1 is 4-pyridylmethyl, R^3 and R^4 are selected from the group consisting of chloro, bromo, fluoro, iodo, nitro, hydroxycarbonyl, lower-alkoxycarbonyl, trifluoromethyl and cyano, and R^2 , R^5 and R^6 are hydrogen.
17. The compound of claim 16 wherein R^3 is chloro and R^4 is fluoro.
18. The compound of claim 1 wherein R^1 is methyl, R^3 is selected from the group consisting of chloro, bromo, fluoro, iodo, nitro, hydroxycarbonyl, lower-alkoxycarbonyl, trifluoromethyl and cyano, and R^2 , R^4 , R^5 and R^6 are hydrogen.
19. The compound of claim 18 wherein R^3 is nitro.

20. A pharmaceutical composition comprising a pharmaceutically acceptable excipient and a compound of the formula



wherein:


R^1 is independently selected from lower-alkyl, cycloalkyl, cycloalkyl lower-alkyl, lower-alkoxy, (lower-alkyl)hydroxymethyl, aryl, arylmethyl, pyridylmethyl,

where aryl, arylmethyl and pyridylmethyl are unsubstituted or independently mono, di or tri substituted with hydrogen, hydroxy, thiol, amino, halo, nitro, lower-alkylthio, lower-alkoxy, mono-lower-alkylamino, di-lower-alkylamino, hydroxycarbonyl, lower-alkoxycarbonyl, hydroxysulfonyl, lower-alkoxysulfonyl, lower-alkylsulfonyl, lower-alkylsulfinyl, trifluoromethyl, cyano, tetrazoyl, carbamoyl, lower-alkylcarbamoyl, and di-lower-alkylcarbamoyl; and

R^2 , R^3 , R^4 , R^5 and R^6 are independently selected from hydrogen, hydroxy, thiol, amino, halo, nitro, lower-alkylthio, lower-alkoxy, mono-lower-alkylamino, di-lower-alkylamino, hydroxycarbonyl, lower-alkoxycarbonyl, hydroxysulfonyl, lower-alkoxysulfonyl, lower-alkylsulfonyl, lower-alkylsulfinyl, trifluoromethyl, cyano, tetrazoyl, carbamoyl, lower-alkylcarbamoyl, and di-lower-alkylcarbamoyl, provided that when R^1 is methoxy, R^4 is not amino or nitro;

or a pharmaceutically acceptable ester, or ether salt thereof.

21. The use of a compound of the formula



Formula I


wherein:

R^1 is independently selected from lower-alkyl, cycloalkyl, cycloalkyl lower-alkyl, lower-alkoxy, (lower-alkyl)hydroxymethyl, aryl, arylmethyl, pyridylmethyl;

where aryl, arylmethyl and pyridylmethyl are unsubstituted or independently mono, di or tri substituted with hydrogen, hydroxy, thiol, amino, halo, nitro, lower-alkylthio, lower-alkoxy, mono-lower-alkylamino, di-lower-alkylamino, hydroxycarbonyl, lower-alkoxycarbonyl, hydroxysulfonyl, lower-alkoxysulfonyl, lower-alkylsulfonyl, lower-alkylsulfinyl, trifluoromethyl, cyano, tetrazoyl, carbamoyl, lower-alkylcarbamoyl, and di-lower-alkylcarbamoyl; and

R^2 , R^3 , R^4 , R^5 and R^6 are independently selected from hydrogen, hydroxy, thiol, amino, halo, nitro, lower-alkylthio, lower-alkoxy, mono-lower-alkylamino, di-lower-alkylamino, hydroxycarbonyl, lower-alkoxycarbonyl, hydroxysulfonyl, lower-alkoxysulfonyl, lower-alkylsulfonyl, lower-alkylsulfinyl, trifluoromethyl, cyano, tetrazoyl, carbamoyl, lower-alkylcarbamoyl, and di-lower-alkylcarbamoyl, provided that when R^1 is methoxy, R^4 is not amino or nitro;

or a pharmaceutically acceptable ester, ether or salt thereof as an anti-inflammatory agent, immunosuppressive agent, anti-allograft rejection agent, anti-graft-vs-host disease agent, anti-allergic agent, anti-asthma agent, anti-rhinitis agent, anti-atopic dermatitis agent, bronchiodilation agent, anti-autoimmune disease agent or analgetic agent.



Formula I